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XSummary
Point mutation in the dystrophin gene accounts for around 20-35% of all cases of 
Duchenne and Becker muscular dystrophies. Detection of the causative mutation in 
each case allows accurate genetic advice to be given to families, opens up the 
possibility of using emerging therapies and gives insight into the pathology of the 
disorder in each case. Novel reports of mutation/polymorphism frequency and type will 
add to the knowledge of the dystrophin gene and protein frmction.
The overall aims of this study were to search for and characterise point mutations in the 
dystrophin gene. This involved the development of a rapid protocol to analyse all 79 
dystrophin coding exons that could be used in a clinical setting. Robotic PCR followed 
by automated dHPLC of a single patient sample at a time identified amplicons 
containing variant sequences. Sequencing was then used to characterise the changes in 
the nucleotide sequence in each of these fragments by comparison to a normal control. 
All the data was analysed and stored in a patient specific database. Restriction digests 
were designed to confirm each o f the mutations and the inheritance of one mutation was 
studied within several pedigrees.
Genotype-phenotype associations in dystrophin were assessed based on repoits of 
increased frequency of mutation in the isoform Dp71 (exons 63-79) in individuals with 
mental retardation. No increase in the fiequency of mutation within the brain specific 
transcript was observed in a cohort o f individuals with learning difficulties, suggesting 
that the distribution of cognitive impairment in affected individuals is too broad to 
screen this region alone in these cases. In this study the sensitivity of dHPLC for the 
coding region was shown to be equal to sequencing.
A study into the incidence of mutation within a single exon in a cohort of 46 individuals 
with DMD/BMD showed that a single mutation within exon 70 occurred three times at 
the same hypermutable CpG dinucleotide. Haplotype studies using microsatellite 
markers and SNP analysis showed that the 3 mutations most likely originated on 
independent backgrounds. This was confiimed by analysis of mitochondrial HVl 
haplotypes showing that a greater degree of similarity existed with a random control
XI
population than between the patients with the same mutation. This evidence suggests 
that certain gene regions may have an increased incidence of mutations.
To assess variance across the dystrophin gene: all 79 coding exons of the muscle transcript 
Dp427 were examined in a total of 22 patients with DMD and 1 with BMD. The overall 
sensitivity of this technique was 96% for recognised and potentially pathogenic mutations. 
Several novel mutations were found, nonsense mutations: 9100C>T, 5159T>A, 754G>T, 
5255T>G, 1357C>T, 5089C>T the splice site mutation: 1150-1G>T and deletion insertion 
mutations: 10205delA, 8438delC, 8405delC, 3036-3037delinsC 1021 -1022insC and 
3201delT. Previously reported mutations were: 10171C>T (3 times), 313A>T, 9337 C>T 
(all nonsense changes). Two single codon deletions were identified - a type of change 
reported only once before in the literature. 10099-101 OldelGAA has been seen once before 
and is associated with a less severe form o f DMD. This variant is believed to affect an 
uncharacterised region of the C-terminal section of the protein. The second single codon 
deletion is novel: 482-484delCCA is expected to delete an amino acid within an internal a- 
helix o f the actin-binding domain in the N-terminal of dystrophin. This variant is believed 
to affect the binding affinity of dystrophin to actin and is associated with a BMD 
phenotype in this study. Two uncharacterised intronic variants were also identified: 1332- 
9A>G is a suggested cryptic splice site mutation within intron 11 and has been reported 
once before; 7098+105_7098+106 insTATTTAATACTTTG is a novel intronic change 
shown to be absent in over 500 chromosomes from the same population. Splice site and 
ESE/ESS analysis of both these changes was performed and has not been reported before. 
Polymorphism frequency within the study population was described with the identification 
of the novel variants: 358-80T>C, 5448+168A>T and 8669-75C>G. One previously 
uncharacterised complex variant is reported as a polymorphism in this study 
(8729 8734delinsTGGTCG). It was also shown that mutation is associated with stretches 
of repeated sequences and CpG dinucleotides distributed throughout the coding sequence.
Analysis for point mutations in the dystrophin gene of patients with DMD/BMD identified 
several novel variants. Characterisation o f these variants has contributed to the 
understanding of dysfunction in the dystrophin gene and identified areas for further study. 
PCR and dHPLC was shown to be a rapid and sensitive means of analysing genetic 
sequence, suitable to large genes with infrequent (but often urgent) referrals.
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CHAPTER ONE
INTRODUCTION
LI General introduction
Duchenne Muscular Dystrophy (DMD) is a common inherited form of muscle disease 
in children. It was first described in detail by an English physician Edward Meryon in 
1852 - work which has since been overshadowed by that of the French physician 
Guillaume Duchenne de Boulogne whose name is now eponymously associated with 
the disease. DMD is an X-linked disorder with an incidence of 1 in 3300 male births 
and the disease is characterised by progressive weakness of the proximal limb 
musculature appearing in early childhood. Affected boys usually become wheelchair 
bound by the age of 12 and most die in their late teens or early twenties from respiratory 
or cardiac failure. In 1982 the gene for DMD (dystrophin) was located to the short arm 
o f the X chromosome (Xp21) and it was confirmed that another X-linked condition, 
Becker Muscular Dystrophy (BMD) was also associated with the same gene. 
Characterisation of the gene led to the identification of the dystrophin protein which 
was shown to be absent from the muscle sarcolemma of affected patients. Subsequent 
work has shown that it is an inherited defect in the dystrophin gene that causes a loss or 
dysfunction of the dystrophin protein resulting in either DMD or BMD.
1.2 Duchenne muscular dystrophy (DMD)
1.2.1 Clinical presentation
The disorder starts in early childhood often presenting with difficulty in walking, 
clumsiness and a tendency to fall. Affected children can have difficulty rising from the 
floor and will adopt the characteristic Gower manoeuvre by climbing up their thighs and 
pushing down on them to extend the hip and trunk (Emery, 1993). Skeletal muscle 
involvement is always bilateral and appears highly selective, this effect has been 
elaborated upon by Bonsett (1969). The muscle weakness in DMD is progressive 
although there are often periods of apparent arrest. Ultimately a wheelchair becomes 
necessary, in most cases by the age of 12 years. Although the skeletal muscle is the 
most affected tissue there is evidence that the cardiac muscle and central nervous 
system are also affected (Blake and Kroger, 2000; Finsterer and Stollberger, 2003). The 
most common cause of deatli is pneumonia compounded by cardiac involvement and 
until recently most cases of DMD died in their late teens or early twenties.
1.2.2 Pathogenesis
The most likely sequence of events in the pathogenesis of DMD is that deficiency of the 
dystrophin protein removes a major link between actin and the extracellular matrix in 
affected tissue. The cellular structure is weakened and this leaves the membrane 
susceptible to disruption when placed under strain (such as when the muscle is in use). 
The damaged membrane allows an efflux of muscle proteins (e.g. creatine kinase) and 
an influx of calcium. The latter leads to mitochondrial overload with ATP depletion, 
decreased oxidative phosporylation and the cell death seen in histochemical analysis 
(Emery, 2002). Fibre structure and surface-volume ratio may be important in explaining 
the fact that certain muscle groups are affected more than others and studies also 
suggested that it may not be the unique absence of dystrophin but the reduction of many 
dystrophin associated proteins that contributes to tissue damage (Sander et ah, 2000).
1.2.3 Laboratory investigations to confirm diagnosis
Confirmation of the diagnosis is essential, not only because o f the serious prognostic 
implications but also for genetic counselling within a family. Normally the serum 
creatine kinase (SCK) level is up to 200 IU/1 but in affected boys the levels at the 
beginning of the disease are elevated 50-100 times noimal (Emery, 2001). As the 
disease progresses SCK levels gradually decline and may approach normal at later 
stages of the disease. Muscle biopsy specimens can be examined histologically and 
immunohistochemically for dystrophin. Investigations show that in the early stages of 
the disease muscle histology may reveal little more than an increased variation in fibre 
size and an increased number of eosinophilic fibres. However, by the time muscle 
weakness is evident fibre necrosis, invasion by mononuclear cells, phagocytosis and 
later replacement with fat and connective tissue are all present (Sewry, 2000). Using 
appropriately labelled anti-dystrophin monoclonal antibodies, in contrast to normal 
muscle, where dystrophin is clearly localised at the periphery of all muscle fibres, in 
DMD there is almost a complete absence of dystrophin apart fi*om occasional positive 
revertant fibres. Revertant fibres are examples where the genetic fault is modified 
locally so that low level restoration o f a partially functioning molecule has occurred. 
Mutation analysis of the dystrophin gene allows determination of carrier status as well 
as confirming diagnosis in the affected individual.
1.2.4 Carrier females
DMD carrier females may occasionally exhibit signs of the disease. This is attributed to 
skewed X-inactivation (Lyonisation) (Azofeifa et aL, 1995). Around 5-10% of carriers 
have some degree of muscle weakness that can begin at any age, symptoms can be 
either progressive or relatively static (Emery, 1993). In manifesting carriers SCK is 
invariably raised and there is some familial concordance between carrier mothers and 
daughters (Moser and Emery, 1974). SCK levels can be as high in asymptomatic 
carriers as in manifesting carriers. Cardiac involvement can occui* in isolation and 
screening for this is recommended in all DMD carriers.
1.2.5 Management and treatment
Until a few years ago there was a general nihilism in the medical profession toward 
therapy in DMD. It is now acknowledged that comprehensive management requiring a 
multidisciplinaiy team approach can make substantial achievements for the patient. 
Promotion of ambulation, the provision of appropriate orthoses and nutritional 
management are all recommended. Early detection and prompt treatment of cardiac and 
respiratory complications is important in effective symptom control and prolongation of 
survival. Pharmacological therapies, in particular glucocorticoids, hold some promise in 
maintaining muscle strength and quality of life (Manzur, 2001). Also the possibility of 
gene therapy has made a resurgence in recent years. Advances have been seen in 
conventional gene-therapies designed to replace a shortened functional protein using 
vectors, plasmids and cell transplantation. Some relatively new strategies have shown 
promising results such as antibiotic induced read through of stop codons, utrophin 
upregulation and anti-sense oligonucleotide exon-skipping (van Deutekom and van 
Ommen, 2003).
1.3 Becker muscular dystrophy (BMD)
1.3.1 Introduction
This disease was named after the well-known German geneticist Prof P.E. Becker. As in 
DMD, others had been first to describe the features of familial muscle weakness and 
pseudohypertrophic calves (Kostakow and Derix, 1937), however it was Becker who 
recognised the disorder as a distinct entity (Becker and Keiner, 1955). Mutations in the 
dystrophin gene cause Becker muscular dystrophy and these mutations are associated 
with the production of a partially functional dystrophin protein. The disorder has a 
much lower prevalence than DMD, with an incidence of around 1 in 18000 live male 
births.
1.3.2 Clinical presentation
The condition has a wide range of onset (2-35 years) but in most cases the first 
symptoms are noticed between the and 18*^ '^ year of life (Emery and Skinner, 1976). 
Usually patients present with symptoms including falling, difficulty with climbing 
stairs, waddling gait and poor running, which can be ascribed to weakness o f the 
muscles of the lower extremities. In exceptional cases the muscle weakness remains 
asymptomatic until very late in life (England et al., 1990). Other symptoms have been 
reported and are covered in greater depth elsewhere (Emery, 2001). Muscle weakness is 
usually symmetrical and starts in the proximal muscles and lower extremities, gradually 
extending to the dorsal muscles and the upper extremities. Muscle hypertrophy may in 
fact precede muscle weakness and affects virtually eveiy limb muscle, though it is 
particularly apparent in the calf muscles. In addition the heart muscle is invariably 
affected and this can be more pronounced than skeletal muscle disorder (Comi et aL, 
1994).
1.3.3 Pathogenesis
In BMD the dystrophin protein is present at the cell membrane but is at reduced levels 
or in an incomplete or altered form. Cell structure is maintained to a greater degiee and 
membrane damage is less severe than in DMD.
1.3.4 Laboratory investigations to confirm diagnosis
Almost all patients have increased SCK levels, usually more than five fold normal 
levels. Histological examination shows a similar picture to that o f DMD although there 
are clear differences. Fibre necrosis is less marked and there is more evidence of 
regenerating fibres (Bradley et aL, 1978). Immunohistochemical staining often reveals a 
mosaic pattern of faintly positive disruptive dystrophin staining. As in DMD, gene 
mutation analysis confirms diagnosis and carrier status.
1.3.5 Disease progression, differential diagnosis and treatment
The course of the disease is not as uniform as in DMD and the clinical picture is 
variable even within the same family. Loss of ambulation can occur between 12 to 70 
years of age, likewise age at death is highly variable (17-74 years) with a mean age of 
40 years - some 25-30 years after the onset of the disease (Comi et aL, 1994). Because 
of the less severe symptoms in BMD manifesting carriers are considered rare; they 
show symptoms of muscle weakness and (exceptionally) heart involvement. There are 
two diseases that mimic BMD; limb girdle muscular dystrophy (LGMD) and spinal 
muscular atrophy type III. In particular LGMD can present as almost identical and in 
some cases only immunohistochemical analysis of the dystrophin related proteins can 
differentiate the two conditions (Emery, 2001). Treatment for BMD involves 
rehabilitation therapy for muscle weakness and regular follow-up for cardiological 
function. Beta-blockers may be used to reduce the risk of cardiac failure.
1.4 X-linked dilated cardiomyopathy (XLDCM)
XLDCM is a rare disorder that is associated with mutations in the dystiophin gene. 
Clinically it appears as similar to mild forms o f BMD although there is a difference in 
the expression pattern of dystrophin. In XLDCM dystrophin is absent in the
myocardium but present in the skeletal muscle (Muntoni, 2003). XLDCM is associated 
with a small number of dystrophin mutations believed to affect tissue specific 
expression of the dystrophin gene.
1.5 The dystrophin gene and proteins
1.5.1 Full length isoforms
The dystrophin gene is the largest gene described in the human genome spanning 
around 2.2 million base pairs o f genomic sequence. Over 99% of the dystrophin gene is 
intronic sequence; the coding sequence is made up of 86 exons (including seven 
promotors linked to unique first exons) (Muntoni, 2003) see Figure 1.1. The full-length 
messenger RNA is predominantly expressed in the skeletal and cardiac muscle with 
small amounts expressed in the brain. There are three isoforms of this full length protein 
each derived from three independent promoters in the brain, muscle and Purkinje 
cerebellar neurons. These three promotors transcribe a unique first exon which is then 
spliced to a common set of 78 exons (Torelli et aL, 1999). Expression of each promotor 
is specific to certain sites, for example the brain promotor drives expression primarily in 
the cortical neurons and the hippocampus whereas the Purkinje promotor is mainly 
expressed in the cerebellar Purkinje cells. The muscle promotor drives expression in the 
skeletal muscle and cardiomyocytes and is also expressed at low concentrations in some 
glial cells in the brain (Muntoni et aL, 1995).
The dystrophin gene also produces variants of each of these principal isoforms, 
generated through alternative splicing events. Both exon skipping and exon scrambling 
have been observed in various dystrophin transcripts (Sadoulet-Puccio and Kunkel,
1996). These events, which occur in a tissue specific manner, generate even further 
protein diversity from the one gene.
1.5.2 Full length dystrophin protein
The protein’s function is to link actin in the cytoskeleton and the dystophin associated 
protein complex at the cell membrane which in turn binds with proteins in the 
extracellular matrix. This structural role for dystrophin acts to stabilise the sarcolemma 
and protect the muscle fibres from long-term contraction induced damage. There have
7
also been suggestions that the protein is involved in cellular communication by acting as 
a transmembrane cell signalling complex (Rando, 2001)
Dp4 27c  I
A).
Dp427p
t
Dp260I Dpl40 Dpi 16 1^ Dp71
ABD 1-3 Spectrin-lke triple hefcal repeats WW BF 2 XC
B).
Figure 1.1 Dystrophin gene and protein organisation. A schematic representation of the 
dystrophin gene. A). The 2.217Mb gene showing the relative distribution of exons and the 
location of each of the seven promotors. The red bars signify exons. The arrows indicate 
promotors (transcribed from centromere to telomere). B). The position o f dystrophin major 
structural domains in relation to the gene sequence, underneath this is a representation of the 
molecule with different shaped regions depicting the different structural elements of the protein, 
ABD = actin binding domain sites 1-3, the 24 spectrin-like repeats are shown interspersed by 
four hinge regions WW= WW domain, EF= EF hand calcium binding domain, ZZ= ZZ zinc 
finger domain, DCC = dimeric coiled coil.
Full length dystrophin is a large rod shaped protein with a molecular weight o f  427 kDa. 
Dystrophin belongs to the spectrin family o f  cytoskeleton proteins and shares the 
common elements o f  this group: an amino terminal actin-binding domain, a central 
triple helical coiled coil domain and a carboxy terminal membrane binding domain 
(Figure 1.1). The actin-binding domain (ABD) has homology with a-actinin and 
consists o f  two calpain homology (CH) domains that are both a-helical globular folds. 
The ABD o f  dystrophin binds to sub-domain 1 o f  actin and has a conserved tertiary 
structure (Norwood et aL, 2000). The central region o f dystrophin consists o f  25 triple 
helical spectrin-like repeats and contains around 3000 residues. The amino terminal end 
o f  these repeats are also involved in actin binding (Sutherland-Smith et aL, 2003). The 
triple helical structure confers an elongated shape to the molecule that is interspersed by 
four hinge regions. The spectrin repeats are poorly conserved but each segment shows a 
common tertiary structure. The hinge regions give additional flexibility to the molecule 
when exposed to the contraction-relaxation forces o f  the muscle. Towards the carboxy- 
terminal there is a cysteine-rich domain o f  around 280 amino acids. The high level o f  
cysteines in this region (15) show strong structural conservation. The carboxy-terminal 
region contains motifs for a WW, ZZ and two (calcium binding) EF hand domains
8
(Winder, 1997). The cysteine rich domain is involved in binding to p-dystroglycan 
which is the principal link to the dystrophin-associated protein complex and the 
extracellular matrix. Finally the terminal 325 amino acids contain binding sites for a l-  
syntrophin and (31-syntrophin and end in a coiled coil motif shared with dystrobrevin to 
which dystrophin is believed to interact with in this region (Sadoulet-Puccio et aL,
1997).
1.5.3 The dystrophin protein and its relationship to other proteins at the muscle cell 
membrane
The dystrophin protein is very similar in structui'e and function to utrophin on 
chromosome 6 and they share all the same protein domains. Utrophin is expressed in all 
tissues and is ‘shorter’ than dystrophin as it lacks some of the helical spectrin repeats in 
the rod region. Because of their similar function some therapeutic strategies have aimed 
at increasing expression of utrophin to compensate for the loss of dystrophin function 
(Perkins and Davies, 2002). In muscle cells dystrophin is the principal linker molecule 
between actin and the cell membrane where it interacts with the dysti*ophin-associated 
protein complex (DAPC) consisting o f dystroglycans and sarcoglycans; utrophin acts as 
the principal actin-membrane link in non-muscle cells by interaction with the 
dystroglycans alone (Winder, 1997). The dystrophin-associated protein complex is the 
link between the extra-cellular matrix and the intracellular (dystrophin anchored) actin 
(Figure 1.2). It is a multi-functional multi-protein complex, with roles in cell signalling 
as well as stability.
Other forms of muscular dystrophy have been shown to arise from mutation in the 
laminin, sarcoglycan and caveolin DAPC protein families. Although dystroglycan 
mutations have not been observed, proteins involved in dysfroglycan glycosylation 
(glysosyltransferases) have also been shown to cause muscular dystrophy (Ehmsen et 
aL, 2002).
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Figure 1.2 The dystrophin associated protein complex (DAPC). A diagram showing the relationships 
of the dystrophin protein with other proteins in the muscle cell. Image adapted from Ehmsen et al., 2002. 
Dystrophin is principally linked to a transmembrane core o f a-dystroglycan, P-dystroglycan which in turn 
is linked to the extracellular matrix via laminin-2. Bound to this dystroglycan core are five 
transmembrane proteins of the sarcoglycan family (a,p,y, 6 and e) which also interact with dystrophin on 
the cytoplasmic surface (Chan et al., 1998). Also associated with the sarcoglycan part o f the complex is 
sarcospan (another transmembrane protein) which binds a cytoplasmic complex o f syntrophins (a, p i, p2 
and yl and y2) (Ehmsen et al., 2002). The syntrophins bind dystrophin near the carboxy terminal and they 
also bind a-dystrobrevein which in turn is associated with dytrophin at its terminal functional domain. As 
well as forming dystrophin-syntrophin-sarcospan interactions dystrobrevin is also involved in linking the 
desmin intermediate filaments to the DAPC via syncoilin (Newey et al., 2000). Cell signalling is 
mediated by caveolin-3 which interacts with the carboxy terminus of P-dystroglycan, caveolin-3 regulates 
nNOS which is involved in production o f nitric oxide an important regulator o f local blood flow (Ehmsen 
et al., 2002)
1.5.4 The smaller isoforms o f  dystrophin
The dystrophin gene has at least four internal promotors that give rise to shorter 
dystrophin proteins lacking successively less and less o f  the amino terminal o f  the full 
length protein but retaining the carboxy terminus domains. All these shorter proteins 
contain the binding sites for dystroglycan, dystrobrevin and syntrophin. Each isoform is 
expressed differently depending on tissue and their functions remain unclear. Each o f  
the internal promotors uses a unique first exon that splices into exons o f  the Dp427m  
transcript (Figure 1.1). Dp260 is expressed in high concentrations in the retina, where it 
co-exists at the synapse between retinal photoreceptor and bipolar cells with the full
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length brain and muscle isoforms (D’Souza et al., 1995). Dp 140 is expressed in brain, 
retina and kidney tissues during development (Lidov et al., 1995). Dpi 16 is only 
expressed in adult peripheral nerves (Byers et ah, 1993). Dp71 is detected in most non­
muscle tissues including brain, retina, kidney, liver and lung and is present in the 
cardiac but not skeletal muscle. Dp71 is the most abundant isoform in the early 
embryonic forebrain, continuing into adult life specifically in the cerebral cortex, 
hippocampus, pituitary and retina (Mehler, 2000). Alternative splicing of dystrophin 
RKA is extensive, tissue dependant and developmentally regulated. Excision of one or 
more exons creates different versions of each isoform lacking small regions o f the 
protein. These findings suggest that dystrophin subserves a wide variety of cellular 
functions that exhibit developmental, regional and neural cell-type specificity. However, 
all these isoforms share similar structural domains implicating the importance o f the 
carboxy terminal end of the protein in the role of mediating different cellular functions.
1.5.5 Dystrophin gene structure
The 79 exons of the principal Dp427m transcript range in size from 23 to 269bp and are 
distributed over 2.217kb of sequence. It has been predicted that the cell takes 16 hours 
to transcribe the complete gene (Tennyson et al., 1995). Intron distances are extremely 
varied with some less than 1Kb and several over lOOkb, the largest is intron 44 (248kb). 
Several clusters o f exons can be identified and these are 20-28, 31-33, 38-40 and the C- 
terminal exons (64-79) which have only four introns over lOkb. Several very large 
introns are found between exons 41 and 63. The dystrophin introns have a high 
concentration of repetitive elements (32.1% overall) with LENE-1 elements representing 
the major contributor to intron size (Toffolatti et al., 2002). There is a direct coiTelation 
between intron size and the number o f repeat elements suggesting an incremental 
growth of the inti’on. Although dystrophin intron size appears well conserved between 
species the expansion of these introns has been shown to have occuired independently 
(Pozzoli et ah, 2003). The role o f increased intron size is unknown but it appears to be 
related to the observation that out-of-frame exons are flanked by significantly larger 
inti’ons than in-frame exons and that larger introns have been shown to stabilise mRNA 
splicing. There is evidence that the recombination events in dystrophin are mostly non- 
homologous (Toffolatti et al., 2002). The rate of recombination in the dystrophin gene 
is influenced by the number of repeats involved in non-homologous recombination 
rather than the frequency of recombination between similar sequences. It is thought that
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the repeat sequences have a propensity to form hairpin sti’uctures which are more likely 
to break and then subsequently rejoin with a change in sequence. Thus a recombination 
introducing more repeated sequence size will propagate further recombination events. 
This may in part explain the high recombination rate across the dystrophin gene, which 
occurs at a frequency of approximately 12% (Abbs et aL, 1990).
1.6 Dystrophin gene mutation
DMD and BMD are caused by certain types of genetic mutation within the dystrophin 
gene. The prevalence of both conditions is maintained in the population by new 
mutation. New mutation almost always occurs in the germline but somatic mutations 
have been observed in both males and females (Smith et al., 1999; Helderman van den 
Enden et al, 2003). The overall ratio between female and male origin o f mutation does 
not deviate from 1:1 but there are suggestions that point mutations arise preferentially in 
spermatogenesis (Grimm et al., 1994). Germline mosaicism of a dystrophin mutation 
was first described by Bakker et al. in 1987 and there is a risk of 5-10% of any 
apparently new mutation recurring in subsequent pregnancies (van Essen et al., 1997).
1.6.1 Deletions and duplications
The most common mutations in the dystrophin gene are intragenic deletions of one or 
more exons, which account for 60-65% of dystrophin mutations. Reports of exon 
duplication are less frequent and range between 5 and 15%, possibly as a result o f the 
sensitivity of techniques used (Muntoni et al., 2003). Both deletions and duplications 
can happen almost anywhere within the gene but most occur within two recognised 
hotspots. The first is the most commonly mutated region and includes exons 44-55. The 
second is in the 5’ region of the gene and includes exons 2 to 19. These hotspots for 
mutation are associated with the presence of large introns, notably intron 44 which 
comprises around 10% of the whole gene alone. These clusters o f mutations represent 
the basis for the use o f the multiplex PCR technique, by the screening of only a set of 
18-28 exons almost all exon deletion mutations can be detected (Beggs et al., 1990; 
Abbs et al., 1991) Quantitative measurement of similar multiplexes also allows 
duplications to be detected with a similarly high level of sensitivity (Yau et al., 1996).
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1.6.2 The frameshift hypothesis
Monaco et al. in 1988 proposed that mutations of the dystrophin gene that maintain the 
translational reading frame might be expected to result in an abnormal but partially 
functional dystrophin in muscle, this would result in the milder Becker type of 
dystrophy. On the other hand, mutations that shift the reading frame are expected to 
cause a truncated protein and would result in virtually no functional dystrophin, causing 
DMD. This frameshift hypothesis holds up in over 90% of cases and is of diagnostic as 
well as prognostic significance. Essentially the dystrophin protein can function in the 
absence of the central and distal rod domains. In some cases expression of an 
abbreviated protein has been associated with symptoms of myagUa and muscle cramps, 
but not muscle weakness (Angelini et aL, 1996). However, when the protein is 
prematurely truncated patients have a very similar severe phenotype of DMD. The 
reason for this effect is thought to be because of nonsense mediated RNA decay 
removing the mutant transcript before it is tianslated into a protein resulting in the loss 
o f the dystrophin mediated link between the cytoskeleton and membrane proteins 
(Hilleren and Parker, 1999).
1.6.3 Exceptions to the frameshift rule
Some patients with BMD have frameshift mutations, these mutations appear to affect 
certain exons, most commonly in the 5' region of the gene. In the case of deletions of 
exons 3-1 it is thought that an additional upstream translation start site (possibly in exon 
8) may be used (Winnard et al., 1995). However this phenomenon is not exclusive to 
mutations in the 5' region of the gene and therefore there must be some other 
mechanism involved in rescuing protein expression. Exon skipping events are routinely 
seen in patients with DMD but usually limited to a few fibres within the muscle tissue 
(revertant fibres). This is where additional exons are removed in RNA processing 
allowing the reading frame to be restored. It is believed that exon skipping is occurring 
at sufficient levels to produce a BMD phenotype in some frameshift mutations. Exon 
skipping is thought to occur in all regions of the gene but it may be limited to certain 
mutations (Nicholson et al., 1992). Even the same mutation in different patients may 
show a different phenotype. One likely contributory factor could be the differences 
between deletion breakpoints within the introns. The splicing process particularly in
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large introns is mediated by several intronic motifs, distributed along the length of the 
intron. Therefore different deletions might affect different exon skipping events 
(Muntoni et aL, 2003). Observations o f inconsistent splicing amongst transgenic mice 
with the same mutation suggest that there are other non-regional factors involved (Lu et 
aL, 2000), with the added possibility of variation in the nonsense mediated decay 
process (KeiT et aL, 2001). This complexity adds uncertainty to predictions of 
phenotype based on mutation type alone and in some of cases confirmation of diagnosis 
by muscle biopsy will be required. Other rare exceptions to the frame-shift rule are in- 
ffame deletions that cause DMD, these have been shovm to remove important functional 
regions of the gene and are in general predictable (Nevo et aL, 2003). Mutations that 
produce a dysfunctional protein are useful in helping to characterise important domains 
of the dystrophin protein.
1.6.4 Point mutations
Around 20-35% of patients with DMD and BMD do not have a deletion or duplication 
of whole exons but instead have a change in the nucleotide sequence of the dystrophin 
gene. These mutations are distributed throughout the gene sequence. In accordance with 
the frame-shift hypothesis, almost all o f the point mutations so far identified in patients 
with DMD are expected to lead to premature translational termination. These constitute: 
nonsense mutations, small ffame-shift deletions/insertions and mutations that affect 
splicing (Roberts et al., 1994). Mutations affecting splicing are varied. Point mutations 
in exon/intron boundaries and deep intronic regions have been shown to cause exon 
excision or cryptic exon insertion shifting the reading frame (Tuffery-Giraud et aL, 
1999). Thus premature translation termination can be caused in a variety of ways. 
Although well conserved the dystrophin gene seems tolerant to a certain amount of non- 
pathogenic sequence variation. Based on this, reports o f in-frame missense mutations 
causing DMD should be regarded with caution until the possibility of another type of 
mutation has been excluded (Roberts et aL, 1994).
The nature of BMD point mutation is more heterogeneous with around 50% shown to 
affect splicing resulting in an in-frame transcript and the rest being missense mutations 
(Roberts et aL, 1994). Exon skipping causing an in-frame BMD transcript has been 
observed with splice site mutations, cryptic splice site mutations and also with some 
nonsense mutations (Fajkusova et aL, 2001; Tuffery-Giraud et aL, 2003). The effects of
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the splicing mutations are often unpredictable fr om observations of the DNA sequence 
alone. The missense mutations reported in BMD cluster around the N-terminal and C- 
terminal regions and are believed to affect the binding domains of each region (Roberts 
et aL, 1994; Norwood et aL, 2000). As the protein is completely retained with a 
missense change these alterations are expected to yield information on the structure and 
function of the dystrophin molecule.
1.6.5 Detection of point mutations
The detection of point mutations in dystrophin presents a considerable technical 
challenge, not least because of the large number of small exons, the large intervening 
introns and the distribution of reported mutations. Muscle RNA has been the target of 
choice for several laboratories with preference for the Protein Truncation Test (PTT) as 
a means of analysing mutations (Roest et aL, 1993). The drawback to these approaches 
is that they require muscle biopsy, an invasive procedure with a risk of complications 
(e.g. bleeding, infection and haematoma formation) of - 1% and one that may often be 
associated with psychological distress for children (Flanigan et aL, 2003). This 
technique does have several advantages particularly with respect to the effects of a 
DNA change on the gene transcript. Splice site mutations, intronic variants and exon 
skipping are all types o f mutation that have been reported using RNA but would present 
difficulties for any DNA based analysis (Tuffery-Giraud et aL, 1999). However, the 
lack of samples has hampered the use of dystrophm mRNA analysis in many cases.
DNA samples are more readily available from patients with DMD, BMD and those 
where there may be a differential diagnosis (Muntoni, 2001). The technology of DNA 
analysis is also well developed and there are many techniques that can be used to 
identify variance within the DNA sequence. Single Strand Conformation Polymorphism 
(SSCP), heteroduplex analysis. Denaturing Gradient Gel Electrophoresis (DGGE) are 
commonly reported ‘scanning’ methods for dystrophin point mutation analysis (Prior et 
aL, 1994; Mendell et aL, 2001; Hofstra et aL, 2004). These are generally based on 
multiplexed PCR being analysed by differences m mobility tlirough a polyacrylamide 
based matrix. High levels of variant detection have been reported in each of these 
methods and with automation these approaches can achieve a rapid analysis of many 
samples. Direct sequencing and Denaturing High Pressure Liquid Chromatography 
(dHPLC) analysis o f the dystrophin gene has also been reported, both these techniques
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are based on the analysis of each exon individually and have very high levels of 
sensitivity (Bennett et aL, 2001; Flanigan et aL, 2003). Although both processes are 
automated, direct sequencing involves a considerable amount of data analysis and 
dFIPLC lüce the other scanning methods required subsequent sequencing to characterise 
the variants. Advances in software are improving the process of sequence data analysis 
and the introduction of robotics has facilitated the application of PCR to gene analysis. 
This will make the choice of both dHPLC and direct sequencing more equitable in 
terms of speed to a multiplexed approach. Given the potential for sequencing, scanning 
methods are still currently prefened due to the high costs of sequencing per amplicon. 
Combining automated PCR with dHPLC followed by semi-automated sequencing is 
expected to provide a system of analysis that is sensitive, rapid and economical.
1.6.6 Genotype-phenotype associations with Dp71
Based on the diversity of transcripts within the gene it has been suggested that 
differences in phenotype in DMD may be influenced by the location of the mutation 
(Moizard et aL, 1998). The Dp71 transcript is the most abundant dystrophin product in 
the brain, it comprises exons 63-79 of the Dp427m transcript with a unique 21 
nucleotide first exon adjacent to its promotor. Although the protein function of Dp71 is 
unknown it has been shown to be involved in the binding of membrane structures and it 
contains the same binding domains as Dp427m (Fabbrizio et aL, 1994). Several reports 
of point mutation within the Dp71 region have been associated with a phenotype of a 
low IQ (<70) (Lenk et aL, 1993; Moizard et aL, 2000,) and Moizard et aL (1998) have 
also attempted to correlate IQ with region of deletion in a large group of patients. In 
these studies the clinical description o f patients with cognitive impairment and a 
mutation in Dp71 ranges fi*om moderate to severe. It has been suggested that a point 
mutation screen of Dp71 coding region in affected DMD/BMD patients with cognitive 
impairment would detect more mutations than in patients without.
1.6.7 Recurrent mutation
If there were consistent evidence for an increased incidence o f either common mutations 
or evidence o f mutational hot spots in certain exons this could be the basis of a staged 
approach to point mutation analysis. The relatively high prevalence of DMD is 
maintained by new mutations that have a short survival within families suggesting that
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most mutations are unique to each pedigree (ten Kate et ah, 1984). Although in BMD 
mutations have a lower prevalence, when these are found there are likely to be more 
members affected due to the higher survival rate of affected individuals (Bushby and 
Gardner-Medwin, 1993). In almost all new cases o f DMD the mutation is therefore 
expected to be unique whilst in BMD there will be a slightly higher chance that the 
mutation may have been observed before. Some point mutations have been reported 
multiple times in DMD, even in the same study, yet no investigations have been made 
to determine background to these mutations (Flanigan et aL, 2003; Hofstra et al., 2004; 
Tuffery-Giraud et al., 2004). Haplotype studies of the dystrophin gene region could 
have thrown light on the origin of these mutations. In BMD a common site of mutation 
could have relevance in the understanding of the protein ftmction or in DMD there may 
be sites of recurrent point mutation apparent only when larger populations of affected 
individuals are studied. Alternatively a mutation could have originated from a common 
ancestor and had been passed through several generations into families unknown to each 
other. Thus the identity of common mutations may be important for mutation strategy 
within specific groups of patients.
1.6.7.1 Assessing the inheritance of a mutation
Each of the teclmiques available for assessing the inheritance o f a mutation have their 
limitations and a combination of approaches may be requned. The use of haplotyping 
using intragenic microsatellite repeats has the advantage of a high level of variance at 
each locus but due to high recombination rate across the dystrophin gene the 
deteimination of inheritance can be limited to immediate relatives only. Occuiring at 
roughly one every two kilobases, SNP haplotyping offers a higher level of resolution 
but can be limited by the low capacity for variance at each locus. The use of 
mitochondrial variable sequences can also be considered in determming maternally 
inherited haplotypes in DMD/BMD families. The mutation rate in mitochondrial DNA 
(average 0.0043 per generation) is high enough to generate a large pool of haplotypes in 
a population yet is considered stable enough for tlie study of these haplotypes through 
tens of generations (Sigurgardottir et aL, 2000).
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1 .6 . 8  Wliole gene analysis
Review of the dystrophin mutation database (www.dmd.nl) shows that point mutations 
in the dystrophin gene have been reported in virtually every exon, although some 
studies using limited point mutation screening have introduced a bias towards individual 
exons of the gene (Prior et ah, 1995). As results from complete studies of the gene 
become available a more accurate picture for mutation distribution and type will be 
available. Combined with quantitative techniques, whole gene point mutation analysis 
offers the possibility of detecting almost all dystrophin mutations. Furthermore, the 
characterisation of any novel base change in current studies is important for the 
interpretation of DNA results in future cases. Observations of polymorphism are 
expected to contribute to our understanding of dystrophin variance in different 
populations.
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1.7 Aims of the present study
• To test the theory that cognitive impaiiment may be associated with a point
mutation in Dp71: analyse dystrophin exons 63-79 in a cohort of patients by
dHPLC.
• Compare dHPLC analysis with sequencing of dystrophin exons 63-79.
• To observe the incidence o f mutation in a single exon: use and evaluate automated
robotic PCR and analyse exon 70 by dHPLC in a cohort of 46 DMD/BMD patients.
• To identify whether the mutation 10171C>T found in three families is on a 
common genetic background.
• Establish a robotic protocol for the PCR amplification of dystrophin exons 1-79 
with analysis of these products by dHPLC followed by sequencing, on a single 
patient basis.
• Analyse a cohort of patients with DMD/BMD for point mutation in dystrophin 
exons 1-79 using the protocol above.
• Characterise any potentially pathogenic variants and evaluate any evidence for the 
cause of each DNA mutation.
• Assess polymorphism in the dystrophin gene within the study population
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CHAPTER TWO
MATERIALS AND METHODS
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2.1 Extraction of DNA from venous blood
Genomic DNA was extracted from peripheral blood lymphocytes. 5-10ml of whole venous 
blood was drawn from the patient and transported in EDTA blood collection tubes 
(Labtek,UK). On receipt in the laboratory the blood was transferred to a 30ml sterile falcon 
tube and diluted to a total volume of 20ml with a solution of 155mM NH4CI, lOmM 
KHCO3 and ImM EDTA. The solution was mixed by gentle inversion and left for 30 
minutes to lyse the erythrocytes.
A white cell pellet was collected by centrifugation at 1300g for 10 minutes at 10“C. The 
supernatant was discarded and the pellet re-suspended by vortexing for 30 seconds with a 
6 ml solution of 2% SDS, 25mM EDTA and left at 37“C for 30 minutes. Addition of 2ml 
lOM ammonium acetate and vigorous vortexing formed a protein precipitate which was 
pelleted by centrifugation at 1300g for 20 minutes. The clear supernatant was then removed 
to a sterile 20ml universal container containing 15ml isopropanol, gentle swirling 
precipitated the DNA forming a clump which could be extracted using a sealed sterile glass 
pipette. The clump was washed in a 70% ethanol solution, air dried for 1 minute and then 
re-suspended in 500pl of TE buffer in a 1.5ml starsted storage tube. The solution was left at 
65“C for 2 hours to dissolve the DNA and then stored at -20°C until analysed.
2.2 Determining DNA concentration
lOpl of the extiacted genomic DNA sample was dissolved in 990pl of dH2 0  by vortexing 
for 2 minutes, this was then transferred to quartz cuvette and the O D 260 of the sample was 
measured in a GeneQuant II spectiophotometer against a dHiO reference sample. The 
OD260 reading was converted to DNA concentration using the following equation:
OD260X 50 X 100 = DNA concentiation (ug/ml)
Where: 50 signifies ug dsDNA per 1 OD260 unit.
1 0 0  signifies the dilution factor.
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2.3 Agarose gel electrophoresis
DNA fragments were fractionated by agarose gel electrophoresis using two commercial gel 
tanks with gels at a variety of concentrations. Volumes used were lOOmI for the 
Electrofast^ (Abgene) 96 well apparatus and 30ml for the Horizon 58® (Gibco BRL) 28 
well apparatus. 1% agarose gels were made using Seachem electiophoresis grade agarose 
(Flowgen) and 2 to 4% agarose gels were prepared using PhoreCus™ agarose (Biogene, 
UK). Gels were prepared by dissolving the desired weight of agarose in 30 or 100ml of IX 
TBE solution, this was achieved by boiling the agarose slurry in a microwave accompanied 
by regular stirring. The molten agarose was then left to cool in a 65°C waterbath. Once the 
apparatus was set up with the appropriate dams, EtBr was added (3ug per 100ml of 
agarose) and the gel poured in. The gels were left to set for a minimum of 1 hour. Once set 
the gel dams were removed and the gels immersed in IX TBE buffer prior to removing the 
combs. PCR samples were then loaded into the wells and run at a constant lOOV until the 
bands under study were resolved. The DNA was visualised on a UV transilluminator (UVP 
Inc) and a CCD image of the gel was then taken and stored as a printed image.
2.4 PCR and oligonucleotide design
2.4.1 Dystrophin sequence data
Sequence data for the coding region of the Dystrophin muscle transcript (Dp427m) was 
taken from Genbank Accession: NM 004006.1. All base changes have been described by 
their effect on this sequence. The nomenclatuie used is according to Antonarakis (1998) 
and den Dunnen and Antonarakis (2000). The intronic sequences were taken from the 
following Genbank files:
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Approximate 5' locus Accession No.
5'UTR, muscle M32058
Exon 2 AL139401
Exon 6 AL121880
Exon 7 U60822
Exon 8 L08092
Exon 9 U06836
Exon 10 AC004468
Exon 17 AL031542
Exon 44 AC069170
Exon 47 AC021166
Exon 51 AC079864
Exon 52 AC025935
Exon 56 AC079175
Exon 57 AC079177
Exon 63 AC078958
Exon 72 AC079143
Exon 79 + 3' UTR AC006061
Each exon nucleotide sequence and 300 hundred base pairs of flanking intronic sequence 
was compiled into a single MS Word document, from this an EMBL format file with all the 
amplicons arranged in gene order was constructed.
2 .4 . 2  Primer design and PCR
Primer sequences amplicon size and the PCR programme used in amplification of 
amplicons containing exons 1 to 79 of the Dp427m transcript are listed in tables 2.1 and
2.2. These primers were designed to amplify each exon of the Dp427m transcript including 
at least 50bp of flanking intronic sequence. Primers were synthesised commercially 
(Sigma-Genosys, UK) and diluted to 5pM concentration according to the manufacturers 
instructions. The primers have been optimised to one of two following reaction conditions; 
All reaction mixes were prepared in 200 pi microtubes (Abgene):
18pl Megamix-without BSA (Microzone Ltd)
2.5pi Sense primer (5pM)
2.5pi Antisense primer (5pM)
2pl DNA (50ng/pl)
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Thermocycler conditions:
File: DMD_45 File : DMD_55
93 °C 5 minutes 9 3 T 5 minutes
14 cycles of 14 cycles of
94“C 30 seconds 9 4 T 30 seconds
55“C (“0.5“C every cycle) 30 seconds 62°C (-0.5°C every cycle) 30 seconds
72“C 45 seconds 72"C 45 seconds
2 0  cycles of 2 0  cycles of
94“C 30 seconds 9 4 T 30 seconds
47°C ("O.rC every cycle) 30 seconds 56°C (-O.rC eveiy cycle) 30 seconds
72“C 45 seconds IT C 45 seconds
PCR programmes were run on a GRI PTC-0200 theimocycler.
Primer sequences came from two sources. Primers taken from Bennet et al. 2001 were 
identified by the label AMER. Primers designed using PrimerS - a web based primer design 
programme (Rozen and Skaletsky, 2000) - have been given the label GLA
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Table 2.1
Primer pairs used and resultant amplicon sizes.
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TABLE 2.2 A list o f amplicons with dHPLC temperatures and elution time shifts using Navigator Software.
DMD DHPLC GLA 5-3-Exon 1 DMD 45 DMD Ex01@55 0 DMDEx01@56 0
DMD DHPLC GLA Ex2 PMD_45 DMD Ex02@54 0 DMD Ex02@S5 0.5
DMD DHPLC GLA Ex3 DMD 55 DMD Ex03@58 1 DMD E x03#61 1.5
DMD DHPLC AMER Ex4 DMD 55 DMD Ex04@56 0 DMD Ex04@59 0.8
DMD DHPLC GLA Ex5 DMD 55 DMD Ex05®56 0 DMD Ex05@57 0.5
DMD DHPLC AMER Ex6 DMD 45 DMD Ex06@56 0 DMD Ex06@59 1.5
DMD DHPLC GLA Ex7 DMD 55 DMD Ex07@57 0 DMD Ex07@60 1.5
DMD DHPLC GLA Ex8 DMD 55 DMD Ex08@56 0 DMD Ex08@59 1
DMD DHPLC GLA Ex9 DMD 55 DMD Ex09@60 0.5 DMD Ex09@61 0 5
DMD DHPLC GLA Ex10 DMD 45 DMD Ex10@57 0 DMD Ex10@58 0.5
DMD DHPLC GLA E xil DMD 55 DMD E x il@57 0 DMD E x il@58 1 5
DMD DHPLC GLA Ex12 DMD 55 DMD Ex12@57 1 DMD Ex12@58 1
DMD DHPLC AMER Ex13 DMD 45 DMD Ex13@55 0.5 DMD Ex13@58 1.5
DMD DHPLC AMER Ex14and15 DMD 45 DMD Ex14/15@55 0 DMD Ex14/15@58 1
DMD DHPLC AMER Ex16 DMD 45 DMD Ex16@57 0 DMD Ex16@59 1
DMD DHPLC GLA Ext7 DMD 55 DMD Ex17@57 0 DMD Ex17@59 1
DMD_DHPLC_AMER_Ex18 DMD_45 DMD Ex18@55 0.5 DMD Ex18@59 2
DMD_DHPLC„AMER„Ex19 DMD 45 DMD Ex19@56 0.8 DMD Ex19@60 2
DMD DHPLC AMER Ex20 DMD_45 DMD Ex20@58 0.8 DMD Ex20@59 0.8
DMD DHPLC GLA Ex21 DMD 55 DMD Ex21@58 0 DMDEx21@S9 0.5
DMD DHPLC GLA Ex22 DMD 55 DMD Ex22@59 0.5 DMD Ex22@60 1.4
DMD DHPLC GLA Ex23 DMD 45 DMD Ex23@58 1 DMD Ex23@59 1
DMD_DHPLC_GLA_Ex24 DMD 55 DMD Ex24@58 0.8
DMD DHPLC GLA Ex25 DMD 55 DMD Ex25@58 0.5 DMD Ex25@59 1
DMD DHPLC GLA Ex26 DMD 55 DMD Ex26@55 0 DMD Ex26@58 0.5
DMD DHPLC AMER Ex27 DMD 45 DMD Ex27@56 0 DMD Ex27@59 1
DMD DHPLC AMER Ex28 DMD 55 DMD Ex28@56 1.3 DMD Ex28@5B 1.5
DMD DHPLC GLA Ex29 DMD_55 DMD Ex29@57 0.5 DMD Ex29@58 1
DMD DHPLC AMER Ex30 DMD 45 DMD Ex30@60 1
DMD DHPLC GLA Ex31 DMD 55 DMD Ex31@57 0 DMD Ex31@58 0.7..............
DMD DHPLC GLA Ex32 DMD_55 DMD Ex32@56 0.5 1.5
DMD DHPLC GLA Ex33 DMD 45 DMD Ex33@57 1 DMD Ex33@58 1
DMD_DH PLC_GLA_Ex34 DMD 45 DMD Ex34@58 1
DMD DHPLC GLA Ex35 DMD 45 DMD Ex35@57 0.5 DMD F y3 5 @ 5 8 0.5
DMD DHPLC AMER Ex36 DMD 45 DMD Ex36@56 0.5 DMD Ex36@57 1
DMD DHPLC AMER Ex37 DMD 45 DMD Ex37@60 0 DMD Ex37@59 0
DMD_DHPLC_AMER_Ex38 DMD_45 DMD Ex38@55 0.5 DMD Ex38@57 1. . . . .
DMD DHPLC AMER Ex39 DMD 45 DMD E x39#55 0 DMD Ex39@56 0.8
DMD DHPLC GLA Ex40 DMD 45 DMD Ex40@56 0.7 DMD Ex40@57 1
TABLE 2.2 (continued) A list o f amplicons with dHPLC temperatures and elution time shifts using Navigator Software.
DMD DHPLC GLA Ex41 DMD 55 DMD Ex41@59 0 DMD Ex41@82 1.5
DMD DHPLC AMER Ex42 DMD 45 DMD Ex42@56 0 DMD Ex42(®57 0
DMD DHPLC AMER Ex43 DMD 45 DMD Ex43@57 1 DMD Ex43@59 2
DMD DHPLC AMER Ex44 DMD 45 DMD Ex44@56 0,5 DMD Ex44@58 1.5
DMD DHPLC AMER Ex45 DMD 45 DMD Ex45@59 0,5
DMD DHPLC AMER Ex46 DMD 45 DMD Ex46@56 0 DMD Ex46@55 0.5
DMD DHPLC AMER Ex47 DMD 45 DMD Ex47@58 0
DMD DHPLC AMER Ex48 DMD 45 DMD Ex48@57 0 DMD Ex48@56 0.5
DMD DHPLC AMER Ex49 DMD 45 DMD Ex49@57 0 DMD Ex49@58 0
DMD DHPLC AMER Ex50 DMD 45 DMD Ex50@58 0 DMD Ex50@60 0.8
DMD DHPLC AMER Ex51 DMD 45 DMD Ex51@59 0 DMD Ex51@56 0.8
DMD_DHPLC_GLA_Ex52 DMD 55 DMD Ex52@59 0 DMD Ex52@60 0.5
DMD_DHPLC_GLA_Ex53 DMD 55 DMD Ex53@58 1 DMDEx53@59 11.5 I
1 1DMD DHPLC AMER Ex54 DMD 55 DMD Ex54@57 0.5 DMD Ex54@61 |2  |
DMD DHPLC AMER Ex55 DMD 45 DMD Ex55@59 0.5 DMD Ex55@60 0.5
DMD_DHPLC„AMEf^Ex56 DMD 45 DMD Ex56@58 0.5 DMD Ex56(S)59 1.3
DMD„DHPLC_AMER„Ex57 DMD 45 DMD Ex57@ ei 0 DMD Ex57@62 1
DMD DHPLC AMER Ex58 DMD 45 DMD Ex58@58 0.3 DMD Ex58@60 1
DMD_DHPLC_AMER_Ex59 DMD 55 DMD Ex59@61 0.5 DMD Ex59@63 1.8
DMD DHPLC AMER Ex60 DMD 45 DMD Ex60@60 1 DMD Ex60@62 i 1
DMD_DHPLC_AMER_Ex61 DMD 45 DMD Ex61@58 1.5 DMD Ex61@60 1.5
DMD DHPLC AMER Ex62 DMD 45 DMD Ex62@60 0.5 DMD Ex82@63 3
DMD DHPLC AMER Ex63s DMD 45 DMD Ex63@58 0.5 DMD Ex63@60 1
DMD DHPLC GLA Ex64 DMD 45 DMD Ex64@59 0.5 DMD Ex64@60 1.5
DMD DHPLC GLA Ex65 DMD 55 DMD Ex65@59 0 DMD Ex65@60 0.5
DMD DHPLC GLA Ex66 DMD 45 DMD Ex68@57 0.5 DMD Ex68@59 0.8
DMD DHPLC GLA AMER Ex87 DMD 45 DMD Ex67@59 0.5 DMD Ex67@60 1
DMD DHPLC AMER Ex68 DMD 55 DMD Ex68@60 0.5 DMD Ex68@63 2
DMD DHPLC GtA Ex69 DMD 45 DMD Ex69@58 0 DMD Ex69@60 1
DMD DHPLC GLA Ex70 DMD 45 DMD Ex70@58 0 DMD Ex70@61 1.5
DMD DHPLC GLA Ex71 DMD 45 0.5 DMD Ex71@61 1
DMD DHPLC GLA Ex72 DMD 55 DMD Ex72@59 0.5 DMD Ex72@81 2
DMD DHPLC GLA Ex73 DMD 45 DMD Ex73@56 0 DMD Ex73@57 0.5
DMD DHPLC GLA Ex74 DMD 55 DMD Ex74@57 0 DMD Ex74@60 1
DMD DHPLC AMER Ex75 DMD 55 DMD Ex75@61 1.2 DMD Ex75@83 1.7
DMD_DHPLC_GLA_Ex76 DMD 45 DMD Ex76@60 0 DMD Ex76@63 1
DMD DHPLC AMER Ex77 DMD 45 DMD Ex77@59 0 DMD Ex77@61 0.3------------------------------------- —!DMD DHPLC GLA Ex78 DMD 45 DMD Ex78@57 0 DMD Ex78@60 0.5 !
DMD DHPLC GLA Ex79 DMD 45 DMD Ex79@57 0 DMD Ex79@59 0.5 1
2.5 Semi-automated sequencing of PCR products
Sequencing was performed on selected amplicons from patients. Genomic DNA was
amplified by PCR as described in method 2.4.2. 3pi of this reaction and 2pl of sucrose
loading mix was loaded onto a 2 % agarose gel and checked for size and intensity alongside
4pi of 1Kb ladder (GibcoBRL). The remaining 22pi of the PCR was added to 4u of Shrimp
Alkaline Phosphatase - which dephosphorylates 5' phosphates on nucleotides (Promega),
8 u of Exonuclease I (New England Biolabs) - which removes nucleotides from single
stranded DNA and 4pi of lOX Exo I buffer (supplied with enzyme). This reaction was
heated in a PCR machine to 37°C for 30 minutes and then the enzymes were deactivated by
incubation at 72°C for 15 minutes. 2pl of the reaction products were then added to a lOpl
sequencing reaction, one containing the sense primer and one containing the antisense
prhner - for amplicon under investigation. Sequencing reactions used the following
conditions in 200pl microtubes (Abgene).
2pl (SAP/£xo I treated) PCR product 
2pl BigDye Version 3 (Applied Biosystems)
2pl of Better Buffer (Microzone Ltd)
3 pi of sHzO 
1 pi of primer (5pM)
Cycled on a GRI PTC-0200 Thermocycler through 25 cycles of
96°C 15 seconds
50°C 5 seconds 
60°C 4 minutes
The products of this reaction were transferred to a 96 well MicroAmp®plate (Applied 
Biosystems) and precipitated out of solution by addition of 5pi 125mM EDTA and 60pl of 
100% ethanol and then left for 45 minutes. The products were then pelleted at the bottom 
of the wells by centrifuging the plate at 1500g for 45 minutes at 10°C. The supernatant was 
removed by inversion of the plate and 150pl of 70% ethanol added to wash the pellet. The 
pellet was then centrifuged again at 1500g for 20 minutes at 10°C, the supernatant removed 
by inversion and the pellet allowed to air dry for 1 hour. Finally the pellet was resuspended 
in 12pl of Hi-Dye formamide (Applied Biosystems). The products were then injected onto 
an Applied Biosystems 3100 capillary automated sequencer using POP-4 matrix (Applied
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Biosytems) to resolve and detect the products. The data generated was automatically 
analysed by the machine's software to produce a trace file containing nonnalised sequence.
2.6 Staden package analysis of sequence data
The Staden package V I.4 (http://staden.sourceforge.net) was used to assemble the 
sequence traces into a database for mutation analysis (Bonfield et aL, 1998). For each 
patient a database was constructed using Pregap4 containing the EMBL format reference 
file described in method 2.4.1. Sequencing files from both the patient and normal control 
were clipped to quality level 20 (Phred 1 error in 1000) and then added into this database, 
the software aligned the sequences against the reference trace in both sense and antisense 
directions. Mutation analysis was performed by visual inspection of the trace subtraction 
line - this represents the difference between the sample and control traces. Each exon was 
visually inspected for mutation, twice in each direction.
2.7 dHPLC methods
Elution gradients for each amplicon were determined by calculation of amplicon length and 
sequence content using the Navigator software (Transgenomic). The elution profile was 
empirically checked for each amplicon, adjusting the time shift parameter to ensure the 
fragment eluted between 1.5 and 2.5 minutes. Table 2.2 lists the methods and time shift 
used for each amplicon.
2.7.1 Manual heteroduplexing and dHPLC analysis in Dp71
Amplicons for exons 63-79 were generated as detailed in method 2.4 using the primers 
listed in table 2.1, Each amplicon amplified from a patient needed to be duplexed with 
another allele before it could be analysed by dHPLC, thus a PCR from normal control DNA 
was always amplified alongside the patient's sample. Cycling conditions were as shown in 
Table 2.2. 3pi of PCR products plus 2pl of sucrose loading buffer were run on a 2% 
agarose gel and the remainder of the patient and control samples were mixed together in a 
96 well thermosprint® plate (Thermo Electron Corporation) in equal quantities based on the
29
intensity of the products on the check gel. The plate was then sealed with a rubber mat 
(Thermo Electron Corporation) placed in a thermocycler and cycled though a programme 
that heats the products and then slowly cools them down encouraging the formation of 
heteroduplexes between different alleles.
Programme for forming heteroduplexes;
95°C for 5 minutes then 90 eycles of 95°C for 20 seconds (-0.8°C at every cycle)
The plate was then unsealed and 30pl of dHPLC low temp standard (Transgenomic) was 
added to an empty well, this was then placed in the loading tray of a 3500HT dHPLC 
machine (Transgenomic).The dHPLC machine was controlled by a pre-defined worksheet 
using Navigator software (Transgenomic). The software specified the method (Table 2.2) 
which was automatically applied to an injection of PCR products fi'om the plate. The 
machine requires a constant supply of four solutions made up with dHPLC grade H2O in 2 
litre volumes:
O.lmM TEAA (Transgenomic)
O.lmM TEAA:25% Acetonitrile (Rathburn, UK) 
75% Acetonitrile (Rathburn, UK)
8 % Acetonitrile (Rathburn, UK)
Data Ifom the dHPLC machine was stored on the contiolling computer and was analysed 
after the samples had run through the machine. dHPLC profiles from all the samples were 
compared against each other, amplicon by amplicon using the Navigator software.
2.7.2 Robotic PCR and dHPLC of Exon 70
An MWG RoboAmp4200 was used to automatically amplify dystrophin exon 70 from 46 
patient DNA samples. A single arm with a lid remover was used as well as liquid sensing 
disposable tips that were automatically replaced after eveiy step involving a change of 
solution. The robot aliquoted 25 pi of a mastermix containing: 240pl sense primer (5pM), 
240pl antisense primer (5pM) and 1700pl megamix-w (Microzone Ltd) into all the wells of 
a 96 well thermosprint® plate (Thermo Electron Corporation). The robot then aliquoted
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300ng of DNA from 46 individual patient samples each into a separate well and then 
aliquoted 300ng of DNA from a single control DNA sample into a further 46 wells on the 
plate. The plate was then transferred to the robot's thermocycler and cycled through the 
DMD_45 PCR programme, once finished 3 pi of sucrose loading mix was aliquoted into a 
96 well thermosprint® plate and a 4pl aliquot of each PCR reaction transferred onto the 
plate. The prepared products were then run out on a 96 well Electrofast® (Abgene) gel to 
check for amplification efficiency. The robot then mixed 24pl of control PCR with each 
patient PCR into a 96 well thermosprint® plate this plate was heated and cooled in the robot 
thermocycler as in method 2.7.1. 30pi of dHPLC low temp mutation standard 
(Transgenomic) was added to an empty well on the plate and this was then placed in the 
loading tray of the 3500HT dHPLC machine (Transgenomic). 5pi of each sample was 
injected under the two elution methods specific for exon 70 (Table 2.2).
2.8 Robotic PCR and dHPLC of dystrophin exons 1-79
2.8.1 Robotic PCR
An MWG RoboAmp4200 was used to automatically amplify all amplicons listed in table
2.2. A single arm with a lid remover was used as well as liquid sensing disposable tips that 
were automatically replaced after every step involving a change of solution. The process is 
summarised in Figure 3.3.1 on page 70. Two reagent plates were used: one containing 
150pl of each sense primer (5pM) aliquoted into a separate well on a 96 well thermosprint® 
plate (Thermo Electron Corporation) and the other 96 well thermosprint® plate with 150pl 
of each antisense primer (5pM) in the same orientation. The robot was programmed to 
transfer 25pl of negative control from 1500pl of megamix-w (Microzone Ltd) to an empty 
well in a new 96 well NCC PCR plate. The robot then mixed 500ng of the sample DNA 
with the mastermix, which was then aliquoted in 23 pi volumes into 50 of the 96 wells on 
the plate. The robot then aliquoted out 3 pi of the sense primers -  only those optimised for 
DMD 45 -  individually into the wells containing DNA and mastermix on the PCR plate, 
followed by the same process for the antisense primers. The plate was then transferred to 
the PCR block and cycled through the DMD 45 PCR programme, once finished the plate 
was removed. The second round of PCR repeated the above process, only with 800pl
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megamix-w being distiibuted into 28 wells and using the primers optimised for DMD 55, 
this plate was cycled thiough the DMD 55 programme. Once finished 3 pi of sucrose 
loading mix was aliquoted into a 96 well thennofast plate (Web scientific) and a 4 pi aliquot 
of each PCR reaction transferred in gene order onto the plate. This was then run out on a 96 
well Electrofast® (Abgene) gel (Method 2.3) to check for amplification efficiency. This 
entire process was repeated to amplify the control DNA.
2.8.2 Heteroduplexing and dHPLC
24pl of sample PCR products and 24pl of control PCR products for each amplicon were 
mixed in turn by the robot and placed onto a 96 well thennofast plate (Web scientific). This 
plate was then was then heated and cooled in the robot thermocycler (Method 2.7.1). 30pl 
of dHPLC low temp standard (Transgenomic) was added to an empty well on the plate and 
this was then placed in the loading tray of the dHPLC machine (Transgenomic). The 
Navigator software (Transgenomic) was programmed to make injections of 17pi using the 
elution methods defined for each amplicon (Table 2.2). Traces were analysed using the 
Navigator software normalisation option.
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2.9 Polyacrylamide gel electrophoresis
2.9.1 Resolving products on a polyacrylamide gel
8 % Polyacrylamide gels were made using the Bio-Rad Protean apparatus with 1mm spacers 
and a 20 well comb. 30ml of dH2 0 , 10ml of 19:1 Acrylamide (National Diagnostics), 10ml 
5xTBE, 250pl of freshly made ammonium persulphate (APS) and 40pl of N,N,N- 
tetramethylethylenediamine (TEMED) were mixed and the gel quickly poured into the gel 
frame. Once polymerised the gel was immersed in IxTBE within its running tank. 4pl of 
samples were mixed with 3 pi of sucrose loading mix and loaded onto the gel and 
electrophoresed for between 2.5 and 6  hours at a constant 340V (Table 2.3).
2.9.2 Silver staining
After electrophoresis silver staining was carried out. The gel was fixed in a solution of 10% 
ethanol/0.5% acetic acid for 10 minutes, the solution was discarded and the gel was stained 
in 0.1% silver nitrate for 15 minutes, after which it was briefly rinsed twice in dH2 0 . The 
bands were developed in a solution of 1.5% sodium hydroxide/0.1% formaldehyde for 20 
minutes or until the bands were of the desired intensity. The gel was fixed in 0.75% sodium 
carbonate for 1 0  minutes, sealed in a plastic bag and photographed for storage.
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2.10 Restriction enzyme analysis
Restriction sites were mapped within an amplicon using a web based programme, 
webcutter (bttp://www.firstmarket.com/cutter/cut2.btml). Primers used to generate a 
restriction site in cases where no natural site was present are listed below:
|Ex70a^ 10171OT ACAGTCTGCACTGGCAGGTAGCCCAlTC Dde 1 55
Ex36as_ 5089 C>T CTCTGATTCATCCAAAAGTGTGTCAGCfT Tru9 1 45
Ex11s_1150-1 G>T GTTCTAATTACAATTGTTAACTTCCTCC Bs/I 45
Ex23as_ 3036 3037delinsC CAAATTCTGATTGATATTTCCGGCTAATGT Dde 1 45
1 Ex24as 3201 delT GGCCATTCCTCCTTCAGAAAAACATfA 7/1/9 1 45
Table 2.4 A list of the primers used to incorporate restriction site in amplicons to 
differentiate between the normal and mutant alleles. Shown are the primer names, 
sequences (with mismatched bases in grey) the enzyme used and the PCR programme 
(Method 2.4.2)
Restriction enzyme digestion of PCR products was performed using a variety of enzymes 
(New England Biolabs). Enzyme reactions were set up in 500pl tubes (Abgene) as follows:
1 Opl PCR product 
2pi Buffer (New England Biolabs)
1 |il Enzyme (New England Biolabs)
5 pi SH2O
2pi Bovine Serum Albumin (New England Biolabs) or SH2O 
Digests were incubated at either 37°C or 65°C overnight.
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2.11 Mitochondrial sequencing
Primers to amplify the HVl region (16009-16390) were taken from (Pfeiffer et al 1999)
F 15971: (TTAACTCCACCATTAGCACC)
R16410: (GAGGATGGTGGTCAAGGGAC)
PCR conditions were as follows:
18pi Megamix-without B S A - (Microzone ltd)
2.5pl F15971 primer (5pM)
2 .5  pi R16410 primer (5pM)
2pl DNA (50ng/pl)
95°C 3min
30 cycles of 
94"C 30sec
55°C 30sec
72"C 45sec
The PCR programme was run on a GRI PTC-0200 thermocycler. Sequencing was then 
conducted as in (Method 2.5). The revised Cambridge reference sequence was obtained 
from http://www.mitomap.org/mitomap/mitoseq.html.
2.12 Splice site analysis and ESE identification
2.12.1 Splice site analysis
Splice site analysis was performed using a web based programme 
http://home.snafu.de/probins/Splice/splice.html; the mutant sequence was given a score 
based on the consensus sequence defined by Shapiro and Senapathy (1987).
2.12.2 ESE analysis
ESE site analysis was performed according to Cartegni et al, (2003 ). The sequence was 
screened for consensus ESE motifs using the described methods and programme.
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2.13 SNP analysis
Entrez SNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) was used to determine the 
location and identity of putative Single Nucleotide Polymorphisms (SNPs). The primers 
designed for amplification of these SNPs are listed below:
dbSNP: 1317642 F-TTTGAAGTGCTGGCAAATGT 
dbSNP:1317642 R-CACAATGAAAGGCAAGGTGA
dbSNP:2178539 F-GGAGGGTGGCTTCATACAAA 
dbSNP:2178539 R-ACCCCAGCAACTCTCCTACC
dbSNP: 1921392 F-CTTTTGGATTAACCTTAGGAA 
dbSNP: 1921392 R-GGCTAAACCAGGGTCCTCTC
PCR and sequencing was as in (method 2.11 and 2.5)
2.14 Robotic sequencing of the dystrophin gene in control DNA
Amplification of dystrophin exons 1-79 was performed as described in method 2.8. The 
robot aliquoted to each well 8  pi of exonuclease mix and incubated the reaction as in 
method 2.5. The robot then aliquoted 7pl of a sequencing mix consisting of 200pl Bigdye 
V.3 (Applied Biosystems) 200pl Better Buffer (Microzone Ltd) and 300pl SH2O into 78 
wells of a 96 well thermosprint® plate (Thermo Electron Corporation). Then 2pi of sense 
primers (5pM) were aliquoted into the plate followed by 2 pi of the PCR products in the 
same orientation as the primers. This was then put though the sequencing cycles in the 
robot’s thermocycler and prepared for sequencing and analysis as previously described 
(Method 2.5).
2.15 Microsatellite and SNP analysis
Primers for the microsatellite and SNP alleles analysed are listed in Table 2.3, including the 
annealing temperature required for amplification modifying method 2 .1 1  and the time 
required for PAGE analysis (Method 2.9). SNP alleles in this group were tested were 
analysed on a 1% agarose gel (Method 2.3).
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2.16 Patients and controls
In total 423 pedigrees have been identified in a database of DNA collected from affected 
members of Scottish families with DMD and BMD from 1982-2004. All individuals had 
contributed samples for testing at the Department of Medical Genetics, Yorkhill with the 
intention of identifying a causative genetic mutation. Patients with a detectable deletion or 
duplication using a routine fluorescent multiplex assay (Yau et al., 1996) were excluded, 
this identified a group of 76 pedigrees as potential cases for point mutation analysis. From 
this group 46 patients were chosen for analysis of exon 70 alone on the basis of a referral 
for DMD/BMD testing being made at a regional neurology/genetics clinic. An additional 
subset of 1 0  patients were selected based on the individual having learning difficulties of a 
degree to warrant special schooling. In Scotland this correlates with an IQ score of 
approximately 70 or less. Finally 18 samples were chosen from the initial group of 76 for 
point mutation analysis of the Dp427m coding sequence based on a confirmed clinical 
diagnosis of DMD, including semm creatine kinase activity over 9000 and/or positive 
family history. 16 control samples were taken from consenting healthy individuals all 
living in the West of Scotland.
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CHAPTER THREE
RESULTS
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3.0 Establishing protocols for dHPLC analysis of dystrophin exons 1-79
Each of the exons in the dystrophin gene was amplified by PCR; amplicons contained 
the full exonic coding sequence and flanking intronic sequence. Primers were designed 
to amplify at least 40bp of flanking intronic sequence to allow efficient sequencing of 
the coding region (Method 2.4). Each primer pair was subjected to PCR of three 
different DNA samples, performed under two conditions, the resulting products were 
evaluated against each other on an agarose gel. The most efficient of the reactions was 
used in all subsequent reactions. When amplicons failed or were of low yield an 
alternative set of primers were designed. Some primers were taken from the publication 
by Bennet et aL (2001) and the remainder were designed using the web-based 
programme PrimerS according to the default criteria (Method 2.4). Each amplicon 
sequence was then entered into the Navigator software and dHPLC elution gradients 
were chosen for optimal detection of mutation within the coding region (Table 2.2). 
dHPLC profiles from homozygous (single allele) samples were saved to a database to 
form a consensus profile for each exon, this was then used to compare against the 
sample profiles for the presence of any variance (Method 2.8.2).
A robotic protocol was devised to amplify all the dystrophin gene amplicons using two 
PCR conditions, extensive practice with water coloured with loading buffer in place of 
reagents ensured that the robot consistently transferred the required volumes for each 
step. When using PCR reagents and control DNA the robot produced products for all 
amplicons (Method 2.8). These products were subsequently used to evaluate the elution 
gradients theoretically determined by the Navigator software. Automated sequencing 
was used to confirm that all dystrophin exons were correctly and specifically amplified 
by the robotic PCR process. A second robotic programme was devised to mix the PCR 
products from two samples together and then heat and slowly cool the mixes (Method 
2.8.2). A spreadsheet was also produced to contain all the dHPLC parameters required 
for analysis of the robotic PCR products. Following this a sample could be robotically 
amplified and mixed with PCR from a control sample before being injected into the 
dHPLC machine using a set template.
Sequencing analysis was designed to use the Staden package of programmes. This 
aligned sequencing traces from a control and patient sample against a reference 
sequence of the entire dystrophin coding region and flanking sequences. In order to test
40
the sensitivity of dHPLC: exons 63-79 of the dystrophin gene from ten samples were 
manually amplified and analysed by automated dHPLC, subsequent sequencing and 
trace subtraction analysis showed that dHPLC detected all the changes observed by 
trace subtraction in the coding region o f all samples (Results 3.1).
The above protocols were used to analyse the dystrophin coding region in an initial 
group of four individuals with known dystrophin mutations (Results 3.3). Shifts 
observed by dHPLC were noted, these were then sequenced and analysed by trace 
comparison against a normal control sequence using the Staden package. Each of the 
four mutations were correctly identified amongst a total of twenty five nucleotide 
changes observed in this group. Based on this a total of 23 patients with a diagnosis of 
DMD or BMD were analysed for variance by dHPLC. This protocol detected a potential 
mutation in 96% of the samples, only one sample failed to show any evidence of a 
mutation. If possible, a restriction digest was designed to confinn a mutation result with 
the introduction of a restriction site (by mismatch in an alternative primer) being 
required in some cases (Figure 3.2.7 and Methods 2.10). All digests showed the 
predicted patterns of bands based on the mutation result. Sequence flanking the 
mutation was analysed for motifs believed to affect mutagenesis. An adaptation of the 
above methods was also used to test the theory that cognitive impairment may be 
associated with a point mutation in Dp71 in a cohort of ten individuals with DMD/BMD 
(Results 3.1).
The inheritance of a recurrent mutation was analysed using published primers for a 
number of well characterised intragenic polymorphisms and some newly identified 
SNPs. The repeat polymorphisms were analysed using polyacrylamide gel analysis 
followed by silver staining using established methods (Method 2.9). The SNPs were 
analysed by restriction digest and agarose gel if already published or direct sequencing 
if unpublished (Methods 2.13,2.15). The mitochondrial HVl region was also sequenced 
in three patients by a method adapted from Pfeiffer et aL, (1999) (Method 2.1).
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3.1 Point mutation in Dp71 and cognitive impairment
3.1.1 PCR and dHPLC of the dystrophin exons 63-79
As the samples being examined were from patients with a muscular dystrophy, the 
region of interest in this study constitutes the coding regions of Dp71 that are shared 
with the muscle transcript Dp427m (exons 63-79). Primers for PCR were designed 
according to method 2.4 and optimised to one of two PCR programmes. PCR design 
was performed with the aim o f simplifying subsequent automation of the process. In 
total 17 amplicons were designed, containing exons 63 to 79 of the Dp427m ti'anscript. 
Using these primers PCR products from 10 patient DNA samples with cognitive 
impairment (Method 2.16) and 12 reactions for a normal control were produced for each 
amplicon (Method 2.7.1). An aliquot of each PCR reaction was run out on an agarose 
gel to check reaction quality within the run, Piguies 3.1.1 and 3.1.2 show photographs 
of the agarose gels of PCR products from patient and control sample DNAs. No PCR 
fails were detected at this stage in the analysis. The samples were then mixed, heated 
then cooled to allow heteroduplexes to form and injected onto a dHPLC column using 
the predetermined parameters for mutation analysis of the coding region contained 
within the fragment (Method 2.7.1). Figure 3.1.1. shows the results o f dHPLC analysis 
of the mixed PCRs from the 10 patients for an amplicon containing exon 79.
Two recognised polymorphisms are known to exist within exons 63-79, these are: 
9649+15C>T and 9974+13_9974+23(A)9-12, their frequency in the UK is unknown but 
is high in other populations. Given this, the number of polymorphisms in exons 63-79 is 
expected to be low, thus dHPLC profiles were compared against each other within the 
group as a measure of variance. dHPLC analysis of amplicons for exons 63-79 using the 
methods described (Method 2.7) showed that exon 70 was the only fragment to show 
shifts using dHPLC in this group of 10 patients - labelled A to J (Figure 3.1.2).
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Figure 3.1.1 PCR and dHPLC analysis o f exon 79 for patients A-J. A.) A 2%
agarose gel photograph showing the 224bp PCR products obtained using primers for 
exon 79, 3 pi o f  product plus 2pl o f  sucrose loading mix was run in each lane alongside 
4pl o f  Ikb ladder. In the upper half are PCR products for patients A-J and in the lower 
half are PCR products for exon 79 from 12 reactions using the same control DNA. Each 
patient PCR was then combined with an aliquot o f  control DNA in equal quantities 
based on the intensity on the agarose gel, this mix was heated and then slowly cooled to 
allow heteroduplexes to form. 5pi o f  each PCR mix was then injected into the dHPLC 
machine. B.) Shown are the dHPLC profiles for each o f  the patient samples mixed with 
the control PCR (plus an unmixed control homoduplex profile) under two separate 
denaturing conditions, 57°C and 60°C. Samples are compared against each other for 
differences within the group -  no shifts in exon 79 were observed under these two 
conditions.
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Figure 3.1.2 PCR and dHPLC analysis o f exon 70 for patients A-J. A.) A 2%
agarose gel photograph showing the 233bp PCR products obtained using primers for 
exon 70, 3 pi o f  product plus 2 pi o f  sucrose loading mix was run in each lane alongside 
4pl o f  Ikb ladder. In the upper half o f  the gel are PCR products for patients A-J and in 
the lower half are PCR products for exon 70 from 12 reactions using the same control 
DNA Each patient PCR was then combined with an aliquot o f  control DNA in equal 
quantities based on the intensity on the agarose gel, this mix was heated and then slowly  
cooled to allow heteroduplexes to form. 5pi o f  each PCR mix was then injected into the 
dHPLC machine. B.) Shown are the dHPLC profiles for each o f  the patient 
heteroduplexes (plus two unmixed control homoduplex profiles) under two separate 
denaturing conditions, 57°C and 60°C. Samples are compared against each other for 
differences within the group. Shifts can be seen at both temperatures in samples E and 
F.
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3.1.2 Characterising variants
A shift in the profiles of exon 70 for patients E and F was evidence for the presence of 
heteroduplexes. To further characterise these shifts, bi-directional sequencing of exon 
70 was performed. Comparison of patient sequence traces against that from the normal 
control revealed differences in the amplicon sequence in both patient samples (Figure
3.1.3):
In patient E a single nucleotide deletion within the coding region of exon 70 was 
observed: 10413 del A (Figure 3.1.3). The deletion of a single base causes a shift in the 
reading fi-ame at codon 3402 (normally coding for a glycine) resulting in a stop codon 
10 amino acids downstream predicted to result in a truncated protein of 3412 amino 
acids in length (G3402fsX3412). The patient was wheelchair bound aged 10 years and 
had a muscle biopsy with abnormal dystrophin staining typical of DMD. The variant 
10413 del A has not been previously reported but is predicted to result in a truncated 
protein, this is consistent with the patient’s phenotype and is considered to be the 
causative mutation in this case. The mutant base change removes the only restriction 
site for the enzyme Mnl I in the exon 70 amplicon (Figure 3.1.4). A study of other 
individuals in the pedigree show that the mutation is present in the mother’s DNA and 
has not been inherited by the proband’s two female siblings, consistent with haplotype 
data from the region (Figure 3.1.5). As grandparental samples were unavailable the 
origin of the mutation could not be confirmed.
In patient F sequencing showed the presence of a single base substitution of a C to T 
within intron 70: 10223+6T>C (Figure 3.1.3). This patient was walking aged 12 years 
and had a muscle biopsy with abnormal dystrophin staining typical of BMD. 
10223+6T>C is a novel base change and its position within the intron makes 
interpretation difficult. The consensus splice site for the human 5' donor is AG/gtaagt, 
Shapiro and Senapathy (1987) defined this as 100% using a scoring system based on 
observations of 1446 5' splice sites in Genbank. The dysti'ophin exon 70 S' donor differs 
from the consensus by the substitution of a terminal C in the exon and a G at position 
10223+3, underlined in the following sequence: AC/gtgagt, this reduces the Shapiro- 
Senapathy score to 83.2. Introduction of the variant reduces the Shapiro-Senapathy 
score to 77.4, the significance of this result is unclear and other splicing factors, such as 
cryptic splice sites, have not been considered in this calculation. Furthermore, no
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mutation within the dystrophin gene has been reported at +6 within the 5' splice site of 
any exon although similar changes have been shown to be pathogenic in other human 
disorders (Scholl et aL, 1999). This variant remains unique and further investigation, 
such as mRNA studies, would be necessary to clarify any pathogenic effect.
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Figure 3.1.3 dHPLC and sequencing o f variants in exon 70. A.) dHPLC profiles o f  
the exon 70 heteroduplexes seen in patients E and F alongside the normal homoduplex 
control. Shown are the profiles at two denaturing conditions (57°C and 60°C) 
demonstrating that under each condition the different variants had different profiles. B.) 
Details o f  sequencing data in Gap4. 2 pi o f  SAP/Exo I treated PCR products from each 
patient were sequenced in a lOpl sequencing reaction using the exon 70 sense primer, 
products were then precipitated in ethanol:EDTA, centrifuged and the residual 
nucleotides washed off. Sequencing products were then re-dissolved in formamide and 
run on an ABI 3100. In each panel the sample sequence is aligned against the normal 
sequence read, below this is a comparison where the traces are subtracted from one 
another, any differences are highlighted by peaks above and below the comparison line. 
The vertical blue line marks the centre o f  the viewing window in Gap4. Sample E 
shows a deletion o f  a single A  nucleotide (Dystrophin 10413 del A, G 3402fsX3412) and 
sample F shows a T to C base substitution (Dystrophin 10223+6T>C).
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ttagttttgaaatcatcctgtcctaaatctgatctcaccatgatctcccttttag ACT ACAT CA
GGAGAAGATGTTCGAGACTTTGCCAAGGTACTAAAAAACAAATT
TCGAACCAAAAGGTATTTTGCGAAGCATCCCCGAATGGGCTAC
CTGCCAGTGCAGACTGTCTTAGBGGGGGACAACATGGAAACtaa
gtagtagcaaaagcagaacacactcttgtttgatgtat
Figure 3.1.4. Restriction digest o f exon 70 amplicon using Mnll. A.) A 2% agarose 
gel showing the results from an Mnl 1 restriction digest reaction o f  PCR products. 1 OOng 
o f  genomic DNA was amplified with primers for exon 70, 8pl o f  this reaction was then 
digested with 20 units o f  Mnl 1 enzyme in a 20pl reaction volume for 12hrs at 37°C and 
15pi run out on a 2% agarose gel alongside a Ikb ladder. The restriction enzyme cuts 
the normal product at 165bp whilst the mutant product remains uncut at 233bp. Lane 1 
is Patient E, lane 2 is a normal control, lane 3 is patient E and lane 4 is an uncut sample.
B.) Below the gel photo is the 233bp sequence o f  the exon 70 amplicon taken from 
Genbank accession no: AC079143. Highlighted in red at position 165bp is the base 
deleted in patient E (10205delA). Exonic sequence is in upper case and intronic 
sequence is in lower case. Sense and antisense primers are highlighted in grey. The 
restriction enzyme Mnl 1 recognition sequence (GAGG) is underlined, this is removed 
in the mutant sequence - the mutant base is highlighted in red. Mnl 1 digest products in 
the normal sequence, are 165bp and 68bp.
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Figure 3.1.5 Pedigree data for family E. Haplotype data from four markers in the 3' 
region o f  the dystrophin gene, showing the immediate family o f  patient E (10205delA). 
Included are results for patient E (11:3), his two sisters (11:1 and 11:2) their father (1:1) 
and mother (1:2). Each sample was amplified by PCR at 55°C using the published 
primers, 4pl o f  this reaction was run on an 8% polyacrylamide gel and detected by 
silver staining. A lleles are numbered according to their relative size, the largest being 1. 
Markers STRHl to lc-2a are informative for this pedigree. STR HI is located in intron 
64 and lc-2a is located in intron 59. A lso included is the result from the Mnl 1 
restriction digest for the familial mutation in exon 70, shown as -  for a normal allele 
and + for the mutated allele. This data shows that neither o f  the sisters have inherited 
the mutation, this is corroborated by the marker results showing inheritance o f  the low  
risk maternal haplotype for the region.
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3.1.3 Sequencing of dystrophin exons 63-79
To determine the sensitivity of dHPLC in this study, patient samples were re-amplified 
and sequenced in one direction (Method 2.5). Sequence data was then compared against 
the normal control for variance within the coding region of each amplicon. No further 
change in the coding sequence of exons 63-79 could be identified in any of the ten 
patients using this method. The sequence data agrees with the dHPLC data for the 
regions screened. The two known polymorphisms with the Dp71 region were analysed 
by sequencing 9974+13_9974+23(A)9-12 showed a frequency of 1/11(9%) for 9A, 
6/11(55%) for lOA and 4/11(36%) for l lA  (Figure 3.1.6), this was not detected by 
dHPLC (Figure 3.1.7). The 9649+15C>T was not observed in any of the samples when 
sequenced (Figure 3.1.8).
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CATCAGGCCAAATGTAACATCTGCAAAGAGTGTCCAATCATTGGATTCAGGTATTAGGAACCAAAAAAAAABjTGTCATTn r r rC T C ~
Tao tvpe FCDS D«ection;+ Coir»nent:"l»FEATURE 000136 ELEMENT 000 COS 123085. 232511 /codon start-1 /label-Exon 68"
B.)
P  1.01* Cokunni: l |2 f 3 ^  Row: 112|3 |4 |5  F  Stxxwconfidence Sjv»«eltrig»j P  Compact
ll37?p/Pal«nLA_Ex68a, It4 7? p /  Pabenl_B_Ei(68as «5 77p/Pati8nl_C.Ex68«
118 77 p /  P«tient_D_E«68as #7 77 p /  Pslieni_E_ExG8a» ll8 77p/PaliBnt_FJ»68«.
tt2 77p/PabenLO-ExBSas #10 77p/PabanLH_Ex68as #1177p/PaliaNJ_ExS8a,
#12 77p/PalianLJ.Ei(68a»
Figure 3.1.6 Sequencing o f exon 68 for patients A-J. Details o f  sequencing data in 
Gap4. 2|il o f  SAP/Exo I treated PCR products from each patient were sequenced in a 
lOpl sequencing reaction using the exon 68 anti sense primer, products were then 
precipitated in ethanol:EDTA, centrifuged and the residual nucleotides washed off. 
Sequencing products were then re-dissolved in formamide and run on an ABI 3100. A.) 
Sequence alignment as shown by Gap4. Data presented is from patients A-J aligned 
against each other and a reference sequence (AC078958). The data shown is a section o f  
the exon 68/intron 68 boundary including the 9974+13_9974+23(A)9-12 polymorphism  
(between bases 23270 and 23280). M issing bases in the alignment are represented by a 
star (*). B.) Sequence traces from the same database as shown by Gap4. The vertical 
blue line marks the centre o f  the viewing window in the software. Data is from each 
patient showing the polymorphic string o f  A nucleotides seen at position 
9974+13_9974+23(A )9-12.
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Figure 3.1.7 dHPLC of exon 68 for patients A-J. A.) dHPLC profiles from 5pi 
injections o f  patientrcontrol exon 68 amplicon PCR mixes for patients A-J. Shown are 
profiles under the two denaturing temperatures o f  60°C and 63°C. There was no 
discernable difference between the samples under these conditions although sequencing 
showed the samples to vary at the poly-A site. B.) An output from the WAVEmaker 
software, demonstrating the predicted melting properties o f  the exon 68 amplicon under 
3 denaturing conditions (54.5°C, 60°C and 63°C). The graph displays helical fraction 
(%) against base position in the fragment, below this is a diagram o f  the gene structure 
within the fragment highlighting the position o f  the exon in red and the poly A repeat at 
position 9974+l3_9974+23(A )9-12. The software shows the fragment to be 100% 
melted at the polymorphic position when at 60°C and 63°C.
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TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATGTAAGTCGTGTATACTAATGCTGTATTCTTTTATTAAT
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Figure 3.1.8 Sequencing of exon 66 for patients A-J. Details o f  sequencing data in 
Gap4. 2 pi o f  SAP/Exo I treated PCR products from each patient were sequenced in a 
I Oui sequencing reaction using the exon 66 antisense primer, products were then 
precipitated in ethanol:EDTA, centrifuged and the residual nucleotides washed off. 
Sequencing products were then re-dissolved in formamide and run on an ABI 3100. A.) 
Sequence alignment as shown by Gap4. Data presented is from patients A-J aligned 
against each other and a reference sequence (AC078958). The data shown is the exon 
66/intron 66 boundary including the 9649+15C>T polymorphism. B.) Sequence traces 
from the same database as shown by Gap4. Data is from each patient showing the 
9649+15C>T polymorphism highlighted by the vertical blue line.
All samples have the C allele at position 9649+15.
53
3.2 A Recurrent mutation in exon 70
3.2.1 Results for robotic PCR and dHPLC
Robotic PCR of exon 70 from 46 patient DNA samples was performed and the resulting 
products checked on a 96 well agarose gel (Figure 3.2.1). Wild type control DNA was 
also amplified in 46 wells alongside the patient samples and the resultant PCR products 
pooled by the robot. Amplification efficiency varied within the group of samples, this is 
most likely due to the presence of contaminants carried over from sample extraction. As 
the protocol involved automated mixing of PCR products from patient and control 
samples, the sensitivity of the dHPLC machine to a range o f sample:control PCR 
concentrations was tested using a known mutation. The results show that detection of a 
heteroduplex is possible even when the ratio of alleles is 5:1 (Figure 3.2.2). It was 
decided that a minimum ratio of 2:1 was to be used routinely. Aliquots of pooled 
control DNA were diluted 1:1 with distilled water and run alongside the sample PCRs 
on the check gel. All 46 patient PCRs gave bands of at least the same intensity as the 
diluted control DNA (i.e. a ratio above 2:1). Subsequently the PCR samples were 
mixed, heated and cooled slowly to allow heteroduplexes to form. Samples were then 
aliquoted onto a plate for dHPLC by the robot (Method 2.7.2). The robot, once 
programmed took eight hours to prepare the samples. dHPLC analysis under two 
denaturing conditions identified 4 samples with a shift from the normal trace.
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Figure 3.2.1 Robotic PCR of exon 70. Robotic PCR o f  exon 70 amplicon from 46 
patient DNA samples (lanes A l-D lO ). 3 pi o f  each PCR product was aliquoted onto a 
separate well on a 96 well plate and mixed with 3 pi loading buffer. These aliquots were 
then loaded onto a 1.5% 96 well agarose gel and run at 80V limiting for 20 minutes. 
Lane D12 contains the N o DNA control PCR and lane D l l  is a blank well. A further 46 
reactions for exon 70 using control DNA was performed alongside and then pooled by 
the robot. 3 pi aliquots o f  the pooled control DNA PCR (diluted 1:1 with water) are 
loaded into lanes E l-12 , this allows for a check o f  PCR efficiency and size o f  product. 
Bands can be seen for all patient PCR reactions, the bands are the same size as the 
control PCR band and are o f  equal or greater intensity.
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C.)
Figure 3.2.2 Sensitivity of dHPLC to heteroduplex concentration. Results from 
experiments designed to test the sensitivity o f  the dHPLC machine. The amplicon for 
Exon 70 was amplified from a sample with a known mutation (10205delA, 
G 3402fsX3412) and a control sample with no variant. To study the effects o f  mixing 
heteroduplexes at varying concentrations (mimicking a reduced efficiency o f  the patient 
PCR) the samples were mixed according to the table below.
0 10 0 0
1 5 5 0
2 5 4 1
3 5 3 2
4 5 2 3
5 5 1 4
6 5 0 5
7 4 0 6
8 3 0 7
9 2 0 8
10 1 0 9
11 0 0 10
The mixes were heated then slow ly cooled and 5 pi o f  each mix was injected onto the 
dHPLC column under denaturing conditions (58°C) and non-denaturing conditions 
(50°C). A.) Shows lanes 1 and 0 under denaturing conditions, demonstrating that a 1:1 
heteroduplex mix reduces the intensity o f  signal slightly. B.) Lanes 1, 3, 5 and 6, (ratios 
o f  1:1, 5:3, 5:1 and complete homozygote at 50% concentration) under denaturing 
conditions. These results show that at a ration o f  5:1 plus dilution o f  signal (mimicking 
poor PCR) a shift in dHPLC trace from normal is observed. However the signal at this 
level is weak, therefore a minimum ratio o f  2:1 was chosen as a suitable threshold for 
the control:patient PCR concentrations. C.) Profiles o f  lanes 1-11 under non-denaturing 
conditions showing the effect o f  mixing lower concentrations o f  PCR products on signal 
intensity.
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3.2.2 Sequence analysis of exon 70 in samples with abnormal dHPLC traces
PCR and sequencing of dystrophin exon 70 from the DNA samples with abnormal 
dHPLC profiles showed the presence of a variant within each of the samples (Figure
3.2.3).
ID Mutation Reported
previously
CK / age Age of  
diagnosis
Residence Familial
cases
w 10099 10101 
delGAA
Yes 8440/ 7yr 7 yrs N. Scot. N
X 10171O T Yes 9500/6yr 6yrs E. Scot. Y
Y 10171O T Yes ll,420/4yr 4yrs SW.Scot Yz 10171O T Yes 9890/6yr 6yrs NW. Scot. N
The variant 10099 10101 delGAA; E3367del has been reported before as present in a 
case o f intermediate muscular dystrophy. An in-frame deletion o f an amino acid is not 
usually associated with the Duchenne phenotype but this variant lies within a highly 
conserved region involved in protein binding in which missense changes have been 
associated with a severe phenotype (Figure 3.2.4). The mutation 10171O T is a 
nonsense mutation changing an arginine to a stop codon (R3391X) and has been 
reported several times before (www.dmd.nl).
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Figure 3.2.3 Sequencing o f exon 70 for patients W-Z. Sequence output from the 
Staden package showing data from the 4 dHPLC variants and a abnormal control 
aligned against each other and a reference sequence (AC078958). A.) The data shown 
in the upper panel is a sequence alignment o f  sequence reads from patients W, X, Y, Z 
and a normal control showing sequence obtained using the Exon 70 sense primer. This 
section covers the exon 70/intron 70 boundary (exon highlighted blue in the reference 
sequence), the variant 10171C>T (R3391X) in samples X ,Y and Z is highlighted in 
orange. Below the sequence alignment is a comparison where the traces are subtracted 
from one another, any differences are highlighted by peaks above and below the 
comparison line, this data shows the C to T base substitution in sample X. B.) Sense and 
antisense sequences from the normal control and sample W. Shown in this section is the 
exon 70/intron 69 boundary (exon highlighted blue in the reference sequence), the 
variant 10099 101 Oldel Glu3367del is highlighted in orange. The trace subtraction 
shows that several bases are different between the samples.
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Figure 3.2.4 Sequence alignment and protein structure of E3367del. An image 
based on data presented in Becker et al. (2003). The figure represents an alignment o f  
amino acids 3300-3375 from human dystrophin and the related sequences in utrophin 
and DRP2 from human and dystrophin from Drosophila m elanogaster and 
Caenorhabditis elegans. Differences to the dystrophin amino acid sequence in the other 
proteins are shown. The E3367del variant is highlighted in red. Highlighted in green are 
reported missense mutations, each affects a conserved amino acid believe to have 
structural significance in the region: C3313F (Flanigan et al., 2003), D3335H (Goldberg 
et al., 1998) and C3340Y (Lenk et al., 1996). Below the sequence comparison is a 
representation o f  the protein secondary structure showing predicted helix structures 
(green cylinders). It is predicted that E3367del removes a conserved amino acid at the 
amino-terminal o f  an a-helix suggesting an important role for this uncharacterised 
domain in dystrophin function.
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3.2.3 Haplotype analysis of a common mutation
The identification of the same mutation (10171C>T R3391X) in three individuals raised 
the possibility that the mutation in these individuals has a common origin. This 
prompted pedigree analysis in each of the three cases to identify any shared haplotype 
between the individuals as described in Method 2.15.
Haplotype analysis for 18 polymorphic markers across the dystrophin gene showed that 
two of the samples (X and Z) shared a haplotype at the 3’ and 5’ regions of the gene but 
did not share a haplotype between markers STR50 and STR45. This result could be due 
to recent recombination within the DMD gene. To help resolve whether the mutated 
alleles shared a common ancestor a database search for single nucleotide 
polymorphisms (SNPs) within the dystrophin exon 70 region revealed 18 SNPs located 
in a 25kb region flanking exon 70. Four of the SNPs had been previously verified in 
dbSNF (www.ncbi.nlm.nih.gov) therefore these four SNPs were sequenced in the 
samples fiom the three patients with the same mutation. Three o f the SNPs were 
heterozygous and added new haplotype information to the microsatellite data. 
Summarising the exon 70 region SNP data: two patients (X and Z) had similar 
haplotypes that differed by only one SNP which was within the region of the mutation. 
The third patient (Y) had a haplotype that differed Ifom the other haplotypes at two 
SNPs (Figure 3.2.5).
Combining the data generated by the SNP and the polymorphic markers it appears that 
the three patients have different intragenic haplotypes but with two of the patients 
sharing ‘blocks’ o f alleles in certain regions of the gene. This result could be due to 
recent intragenetic recombination within a common ancestral gene. To investigate this 
mitochondrial haplotyping was carried out.
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Recombination Exon no. Polymorphic markers
Frequency ( % )  
1
DYS I _   ^
D Y SII ( A . )
S 7 -Î5  X m n I ni
Exon 67
4£  YD X S997
Exon 68 
Exon 69 
Exon 70 Exon 71
DYS I 
DYS IIB 
5'5n1 
STR7A 
STR7B 
87.8 Taq I 
87.15 Xmn I 
5'7n4 
STR45 
Ex48 Msel 
DXS997 
STR50 
DXS1038 
1c2CA 
J66 
3'19n8
SNP 1317642 
SNP 2178539 
SNP 3833412 
SNP 1921392 
STRH1 
3'DYS
1 1 1 0.611 2 1 0.771 2 0.571 1 1 0.681 1 1 0.441 1 1 0.511 2 0.491 1 1 0.521 1 0.891 1 1 0.671 3 ' 0.701 0.721 2 0.731 1 1 0.511 1 0.131 1 1 0.581 1 2 0.121 1 1 0.161 1 0.451 1 0.391 1 1 0.782 1 2 0.34
10171C>T
Exon 72
Single nucleotide polymorphisms
dbSNP: 1882265 - NV-  dbSNP: 1317640 - NV-  dbSNP: 1317641 - NV dbSNP 1317642 -0 .128/0.872-  dbSNP 1882264 - NV dbSN P;1317179-NV-  dbSNP:2404498 - NV
dbSNP 2 1 7 8 5 3 9 -0  167%) 833
dbSNP 3833412 - 9974+13_9974+23(A)9-12
  10171OT
dbSN P:1344095-N V  
dbSN P;1921395-NV  
dbSNP;2404497 - NV 
dbSNP:3747385 - NV 
dbSN P:1921394-NV  dbSN P:1921396-NV  dbSN P:2178538-NV  dbSNP:1921392 - 0.149/0.851 
dbSNP;2404496 - NV
Figure 3.2.5 Microsatellite and SNP haplotyping (A .) Depiction o f  the dystrophin gene (2.4Mb) 
showing recombination frequency between labelled exons. In orange are the polymorphic markers, 
positioned in their relative location in the gene. The position o f  mutation 10171 C>T is highlighted 
in pink. (B.) Detail o f  the region between exons 68 and 72 showing the SNPs identified in genebank. 
SNPs are identified by their Genbank number followed by the registered heterozygosity. NV  = not 
validated in the database. SNPs used have been highlighted in blue. (C.) Haplotypes for patients 
X,Y and Z for all the markers studied. A lleles are labelled by relative size, 1 being largest. Markers 
where patients X and Z differ are highlighted in green.
3.2.4 Mitochondrial hypervariable region 1 (HVl) haplotyping.
Mitochondrial hypervariable regions have been shown to be capable of establishing a 
common genetic origin via the maternal (therefore X-linked) lineage (Richards and 
Macaulay, 2001). The hypervariable region 1 (HVl) of mitochondrial DNA is a 
commonly used region to establish mitochondrial ancestry. This region was therefore 
analysed in the three patients and also in fifteen control samples (method 2.11).
The results for all samples analysed revealed 24 base changes which allowed the 
identification of 14 haplotypes within the HVl region (Figure 3.2.6). The patients who 
carried the identical DMD mutation each had different haplotypes. Two of the patient 
haplotypes were also found in the control samples. The consensus mitochondrial 
sequence was the most common haplotype in the study group, being present in 1 in 6 of 
the samples tested. Two other haplotypes (16356 T>C and 16093T>C: 16224 T>C: 
16311 T>C) were seen at a fi-equency of 1 in 9. This Ifequency is similar to that found 
in the Welsh population where HVl haplotypes have been shown to be relatively 
homogeneous (Richards et a l, 1996). The HVl data shown here suggests a similarly 
low level of mitochondrial diversity exists in the control sample population.
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Figure 3.2.6 Mitochondrial H Vl haplotyping. Sequencing o f  the mitochondrial H Vl 
region (base pairs 16009 to 16390) in 15 control samples and patients X,Y and Z. Only 
bases where a change was observed from the Cambridge reference sequence 
(http://www.mitomap.org/mitomap/mitoseq.html) have been listed. Base numbers are 
listed in the column on the far left and sample ID numbers are in the first row. 
Individual results are in columns and have been aligned in order o f  first base change 
from the consensus sequence in the direction 16390 to 16009. Columns have been 
shaded according to the haplotype generated. Individuals with the same haplotype have 
the same shading. Patient haplotypes are emphasised in bold. Samples Z, 30 and 34 
share the same consensus haplotype. Samples 38 and 28 have the same haplotype 
(16356 T>C) and samples X and 18 have the same haplotype (16093T>C, 16224 T>C, 
16311 T>C), all other individuals have a unique HVl haplotype in this sample set.
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The conclusion from the haplotype analysis is that the mutation 10171C>T has 
independently arisen on at least three different occasions. The three families therefore 
do not represent a founder effect for this mutation.
To study the origins of the mutation in each of the pedigrees, samples fr om family 
members were analysed for the presence o f the mutation.
3.2.5 Mutation analysis in family members.
To test for the 10171C>T mutation in other family members a PCR-based analysis of 
the mutation was developed, A primer was designed that incorporated a Dde I 
restriction site in the presence of the mutation. The primer has a C to A mismatch at the 
3"^  ^3' base and incorporates a G/C base in the final PCR product (Figure 3.2.7). Samples 
from family members were collected and a study into the inheritance of the mutation in 
each pedigree was performed. The results show that in the pedigree of individual Z the 
mutation is present in the patient’s mother but not in his maternal grandmother (Figure 
3.2.8). In this family the mutation appears to be a new mutation either in the germline of 
the grandparents or an early embryonic mutation in the mother. From the haplotype 
data: Individual Z shared several alleles with individual X (Figure 3.2.5). In the 
pedigree o f individual Y the mutation was shown to have originated in a generation 
previous to that for which DNA samples were available. In this large pedigree several 
males were affected with one manifesting carrier diagnosed aged 5 years (Figure 3.2.9). 
Samples for pedigree X were limited to the immediate family, showing that the 
mutation was present in the affected patient’s mother (Figure 3.2.10) and no samples 
were available for pedigree analysis of patient W.
The sporadic nature of the mutation is shown by the results from the family study of 
patient Z. Patient Z had a similar dystrophin haplotype to patient X (Figure 3.2.5). The 
other pedigree results did not provide evidence as to the origin o f the mutation in these 
families.
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Wild type sequence: CATCCCC^GAATG Base pairs 10165 to 10176
Mutant sequence: CATCCC&GAATG Accession no. NM_004006.1
Antisense primer introduces a mismatch at base no. 10174, highlighted in green:
Polymerase extension
Primer sequence: ^ CTjBACCCGATGGACGGTCACGTCTGACA
Genomic sequence: CATCCCNGAATGGGCTACCTGCCAGTGCAGACTGT
Amplicon sequence with incorporated D de  I restriction site in the mutant allele:
Wild type sequence: CATCCCËGA # T G
Mutant sequence: CATCCC0GA@ TG Dde I restriction site CTNAG in red
New  amplicon size: 168bp
Digest products: wild type allele: 168bp mutant allele: 140bp/28bp
B.)
Ladder band at 
201 bp-
Figure 3.2.7 Generation o f a Dde I restriction site and digest results. A.) The
mutation 10171C>T R3391X does not alter a natural restriction site so a primer was 
designed to incorporate a D de  I restriction site in the presence o f  the mutant base. A 
new antisense primer o f  28 oligonucleotides in length introduces a mismatched base at 
base no. 10174 (Accession no. NM 004006 .1 ) used with the original sense primer it 
produces an amplicon o f  168bp in length. D de  I will excise the terminal 28 base pairs in 
the mutant amplicon. Digestion products were resolved on a 3% agarose gel. B.) An 
agarose gel showing the results from a D de  I restriction digest reaction o f  PCR products 
o f  the amplicon described above. lOOng o f  genomic DNA was amplified using the 
mismatched antisense primer and the exon 70 dHPLC sense primer, 8pl o f  this reaction 
was then digested with 20 units o f  D de  I enzyme in a 20 |l i1 reaction volume for 12hrs at 
37°C. 15|al o f  this reaction was run out on a 3% agarose gel alongside a Ikb ladder. 
Lane 1: 10171 T>C affected patient. Lane 2. 10171 T>C obligate carrier. Lane 3: 
10171T>C affected patient. Lane 4: Normal control. Lane 5: N o DNA control. Lane 6:
1 kb ladder.
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Figure 3.2.8 Pedigree data for family Z. Pedigree for patient Z (111:2) affected by 
DMD mutation 10171C>T. Availability of DNA samples for all individuals related to 
the proband’s mother is indicated. The result Ifom the PCR followed by Dde I 
restriction digest is shown by a + for the presence of the mutant allele and a -  for the 
presence of a normal allele. When a DNA sample was unavailable the individual is 
marked as: No DNA. The mutation is seen in the proband’s mother (11:2) but not in his 
half brother (111:3). The proband’s maternal aunt (11:4) does not carry the mutation nor 
does his maternal grandmother (1:2). This data shows that the mutation originates from 
the grandparental germline - haplotype studies were not conducted.
6 6
HUÎKoDfW HaOWA
N-A No DNA IV;?
IV14
NaONA Wl» No ON*
Figure 3.2.9 Pedigree data for family Y. Pedigree for patient Y (IV: 16) affected by DM D  
mutation 10171C>T. Availability o f  DNA samples for all individuals related to the obligate 
carrier mother indicated. The result from the PCR followed by Dde  1 restriction digest is 
indicated by a + for the presence o f  the mutant allele and a -  for the presence o f  a normal 
allele. When a DNA sample was unavailable the individual is marked as: No DNA. There 
are seven affected males in this pedigree identifying several obligate carriers. This data shows 
that the mutation can be traced back to the great-grandparents o f  patient Y, its origin cannot 
be determined. 1V:8 is a manifesting carrier with symptoms o f  muscle myopathy.
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No DNANo D N A
11:711:2 No DNA
111:81)1:3 111:7111:2 111:41 1 1 :1
No D N A  + No DNA No DNA No DNA No DNA
Figure 3.2.10 Pedigree data for family X. Pedigi'ee for patient X (111:1) affected by 
DMD mutation 10171C>T. Availability of DNA samples for all individuals related to 
the proband’s mother indicated. The result from the PCR followed by Dde I restriction 
digest is indicated by a + for the presence of the mutant allele and a -  for the presence 
of a normal allele. When a DNA sample was unavailable the individual is marked as: 
No DNA. The mutation is seen in the proband’s half brother (111:3) and mother (11:2). 
Neither of the two maternal aunts carried the mutation. No DNA sample was available 
from the maternal grandparents. Haplotype studies were not conducted.
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3.3 dHPLC analysis of dystrophin exons 1-79
3.3.1 Assay design
3.3.1.1 Primer selection
Results from the primers designed to screen dystrophin exons 63-79 by dHPLC has 
already been described in Results 3.1. Primers for each of the remaining dystrophin 
exons 1-62 were subjected to PCR at two conditions (Methods 2.4.2) with the most 
efficient of the two reactions chosen as the final programme. Where a reaction failed 
new primer sets were optimised to produce a single (exon containing) amplicon at one 
of the two PCR programmes.
3.3.1.2 Robotic PCR and dHPLC
Robotic programming allowed amplification of each amplicon from a single DNA 
aliquot within a single programme (Figure 3.3.1).
Robotic manipulation was then used to mix PCR products (exons 1-79) from the patient 
and control DNA samples (Figure 3.3.2) which were subsequently heated and cooled to 
allow heteroduplexes to form. The resultant mixes were then automatically injected onto 
a dHPLC column under conditions specific to mutation detection within the exon of 
each amplicon (Methods 2.8.2).
As a preliminary test to confirm that all the exons had been correctly amplified using 
the robotic protocol; automated unidirectional sequencing of all PCR amplicons fiom 
the control DNA sample was performed. Subsequent constmction of a Gap4 database of 
these sequencing traces in the Staden package showed that each exon had been 
amplified correctly (Figure 3.3.3).
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A.)
Sense Piiinei s Antisense Pi iinei s
Clieck platePCR PLATE for DMD 55 Proaram m ePCR PLATE for DMD 45 Program m e
(jenoniic L)NA
PCR master mix PCR master mix
Figure 3.3.1 Robotic PCR o f  dystrophin exons 1-79. A schematic representation o f  
the robotic steps involved in automated PCR o f  the dystrophin gene. Liquid transfers 
are represented by numbers, in the order they are performed on the robot. 1) A 25pi 
aliquot o f  (negative control) mastermix is transferred to the DMD 45 PCR plate. 2) 
500ng o f  sample DN A is mixed into the mastermix. 3) 23 pi aliquots distributed into the 
PCR plate. 4) 3 pi o f  sense primers (amplicons optimised to DM D 45) are added. 5) 3pi 
o f  antisense primers (amplicons optimised to DM D 45) are added. 6) plate is cycled 
through DMD 45 programme. 7) A 25 pi aliquot o f  (negative control) mastermix is 
transferred to the DM D 55 PCR plate. 8) 500ng o f  sample DNA is mixed into the 
mastermix. 9) 23 pi aliquots distributed into the PCR plate. 10) 3 pi o f  sense primers 
(amplicons optimised to DM D 55) are added. 11) 3pl o f  antisense primers (amplicons 
optimised to DM D 55) are added. 12) plate is cycled through DM D 55 programme.
13) 4pl aliquots from each PCR reaction are arranged onto a check plate in the order the 
amplicons are found in the gene. The products in the check plate are then run on a 96 
well 1% agarose gel. Below are two photos o f  such gels. B.) A gel image showing 
correct amplification o f  all amplicons from the normal control, exon numbers are given  
for the bottom row. Negative control lanes for DMD 45 (A) and DMD 55 (B) are also 
highlighted. C) A gel image from a patient with a dystrophin deletion o f  exons 44-53, 
shown by the absence o f  bands for these exons.
B.)
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A.)
Patient PCR products
DMD_45 plate DMD 55 plate
DMD 45 plate DMD_55plate
Conbol PCR products dHPLC pk*eI
HETTROCMJPLEX
DMD Ex01@55 DMD Ex02@54 DMD Ex03@58
DMD Ex04@59 DMD Ex05@56 DMD Ex06@56
DMD Ex07@60 DMD Ex08@56 DMD Ex09@60
Figure 3.3.2 Forming heteroduplexes and dHPLC analysis. A.) Schematic 
representation o f  the robotic steps involved in automated mixing o f  PCR products from 
the patient sample and the control sample. Products from the two samples for each 
amplicon are mixed (24pl each) and placed in a 96 well plate. This is sealed, heated and 
then cooled slowly, allowing heteroduplexes to form. 17pl o f  each amplicon mix is then 
injected onto the dHPLC column using the elution profiles and temperatures determined 
by the Navigator software. B.) Examples o f  dHPLC traces for amplicons containing 
DMD exons 1 -9 . Each pane shows the results from one elution method for sample ID 
No.5. The sample result is highlighted in brown, the other traces are normal control 
(homozygous) results from previous runs and were used for comparison. The traces 
have been normalised to account for any differences in intensities between the samples. 
These results show that sample No.5 does not show any difference from known normal 
controls in all the traces shown here apart from exon 3. The shift observed in exon 3 
(identified by the red arrow) was shown by sequencing to be a heteroduplex caused by 
the presence o f  the 94-9dupT polymorphism in the control PCR, it was not present in 
the patient PCR.
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F igure 3.3.3 Autom ated sequencing o f  dystrophin exons 1-79. Above is a detail from 
an alignment o f  sequences in Gap4. The data is from unidirectional sequencing o f  
dystrophin exons 1-79 in control DNA. Amplicons for each exon were robotically 
amplified and then purified using SAP/£jco I. These purified products were then 
checked on an agarose gel and 3pi was robotically added to a sequencing reaction 
containing the sense primer specific to the amplicon. The resulting products were 
resolved on an A B I3100 analyser. Shown in this detail are alignments for exons 20 to 
39 from the normal control. Exons are highlighted in blue on the red upper reference 
line, clipped sequence that matches the reference sequence is shown by the red arrows, 
the blue lines represent the (clipped) remainder o f  each sequence read (this extends past 
the sequence o f  the PCR product and includes background from the capillary). The red 
highlight at exon 26 shows the presence o f  variance at the poly A tract 5' to exon 26 
(3603+15). Comparison o f  sequence reads against the reference sequence (Method 
2.4.1) showed several variants: 94-9dupT, 1993-37G>T, 2645G>A, 3603+15dupA, 
8027+1 l O T  and 8669-75C>G.
CONTROL DNA
Antisense Primers Sense Pnmers
Primer
Removal
S E Q U E N C E !
Above is a schematic diagram showing the automated steps in the robotic sequencing o f  
dystrophin exons 1-79 for dHPLC analysis. 500ng o f  control DNA is mixed with a PCR 
mastermix and aliquoted onto a plate. The DNA is amplified in two PCR programmes 
(red/green wells) using aliquots o f  sense and antisense primers (Figure 3.3.1). 4pl o f  the 
resulting PCR products are resolved on a 1% agarose check gel. An SAP/Exo I digest is 
used to remove residual primers and free nucleotides from the remainder o f  the PCR 
reactions. A 3 pi aliquot o f  each reaction - arranged in the same order as the PCR plate - 
is then added to a 7pl aliquot o f  sequencing reagents on a sequencing plate. The sense 
primers are then aliquoted into the sequencing plate using the same alignment as the 
initial PCR, this ensures that the primers correspond to the amplicons in the reaction. 
Finally the robot performs a cycle sequencing reaction and the products are then 
manually prepared for resolving on an automated sequencer.
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3.3.2 Point mutation analysis in dystrophin exons 1-79.
3.3.2.1 Establishing consensus traces and identification of common polymorphisms
Initially four samples (with a previously identified mutation) were analysed by dHPLC 
for the presence of heteroduplexes within exons 1-79 of the dystrophin gene. dHPLC 
analysis was performed under the described conditions and profiles were compared 
using the Navigator software to a control sample mixed with itself to form 
homoduplexes (Method 2.8.2). Profile comparison indicated the presence of 
heteroduplexes at the sites of all four mutations and also highlighted the presence of 
several polymorphic variants within the patient samples that were confirmed by 
sequencing (Table 3.3.1). Consensus traces of each exon profile where no variance was 
observed were normalised using the Navigator software and saved to a database. The 
consensus trace for each exon was then used as a reference against which further sample 
profiles were compared.
3.3.2.2 Analysis of patient samples
In total DNA samples from 21 cases of DMD, 1 case of intermediate DMD and 1 case 
of BMD were analysed for point mutation in dystrophin exons 1-79 by robotic PCR 
followed by dHPLC. All amplicons for each patient could be amplified by PCR, 
excluding exon deletion in all cases. Sequencing of amplicons in which a shift was 
identified was performed on the patient and conti'ol samples (Method 2.5) and traces 
were visually compared against each other using the Staden package of programmes. In 
all cases where a pathogenic mutation was identified the sample was re-amplified and 
(if possible) an alternative method was used to confirm the sequencing results. The 
results from this analysis are listed in Table 3.2.
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3 94-9dupT - 0.09 0.10 EUR
6 358-80T>C - 0.04 -
13 1483-123G>T - 0.22 0.25 AMER
13 1483-110A>G - 0.22 0.48 AMER
14 1635A>G R454R 0.17 0.10 EUR
14 1704+51T>C - 0.17 0.20 EUR
17 2160+13T>C - 0.52 0.80 EUR
17 1993-37G>T - 0.26 0.30 EUR
21 2645G>A G882D 0.17 0.15 EUR
31 4234-13A>G - 0.09 0.10 EUR
37 5134G>A R1745H 0.17 0.30 EUR
38 5448+169A>T - 0.43 -
41 5922+77_5922+78del - 0.04 0.20 AMER
43 6118-63_6118-62dup - 0.13 0.10 EUR
43 6290+27T>A - 0.04 -
44 6291-115G>A - 0.17 0.20 EUR
48 7096C>A K2366Q 0.17 0.20 EUR
49 7200+53C>G - 0.26 0.30 EUR
53 7728 T>C N2576N 0.09 0.20 EUR
54 8027+11C>T - 0.22 0.15 EUR
59 8669-75C>G - 0.87 -
59 8810A>G Q2937R
[E2910G;
0.04 0.10 AMER
59 8729 8734delinsTGGTCG N2912D] 0.09 -
Table 3.3.1 A list o f  the polymorphisms found in this study. The first column indicates 
the amplicon (exon) in which the change is found, the second column is the nucleotide 
description - nomenclature is according to Antonarakis (1998) and the reference 
sequences are as given in Method 2.4.1. The next column is any amino acid changes 
that are caused by the polymorphism. Then the next column lists the frequency o f  the 
change in this study o f  23 individuals and next to that, the observed frequency taken 
from the locus specific database http://www.dmd.nl. The label EUR indicates that this 
was taken from a report on a European population and the AMER label shows this was 
from a report on an American population. ( - )  indicates that the polymorphism is either 
novel or reported as rare (once per study) in the database.
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3.3.3 Sensitivity of analysis and location of variants:
O f the 23 patient samples studied a recognised cause o f the disorder was found in 18 
(78%). When the two single amino acid deletions and a further two likely causative 
splice site mutations the detection rate rises to 22/23 (96%) in this group of patients. 
This is similar to a previous report for dHPLC sensitivity on dystrophin (75% in eight 
patients, the remainder having duplications) (Bennett et aï., 2001). 18 of the 21 cases 
with a diagnosis of DMD (85%) had a recognised mutation. Only one o f the mutations 
was seen more than once (1017C>T) and the remainder were distributed thr oughout the 
gene sequence. More than one mutation was found in exons 70, 37 and 57 with exon 70 
having 4 recognised mutations and one amino acid deletion (1099 lOlOldelGAA).
3.3.4 Mutation type and mechanisms of mutagenesis
3.3.4.1 Base substitutions
The variant nucleotides and local DNA sequence surrounding each potentially 
pathogenic variant are listed in Figure 3.3.4: highlighted are features in the DNA 
sequence that may have participated in the generation of the variant. 13/23 of the 
variants are single base substitutions, with 11 of these 13 generating a stop codon. The 
remaining two substitutions are believed to affect splicing. 5 of the stop codons 
generated were CGA>TGA, which has been implicated as a likely target for the 
antibiotic nonsense read-through therapies. The same 5 CGA>TGA mutations made up 
all the substitutions located in CpG dinucleotides (38% of all substitutions) which is 
higher than previously reported in dystrophin (Todorova and Danieli., 1997) but similar 
with that of a genome wide study (Cooper and Krawczak., 1990), The 
transition:transversion ratio of all the substitution mutations is 2:1 which is the same as 
previously reported figures. Small repeat sequences were frequently seen in the 
immediate flanking sequence o f the substitution mutations, it has been suggested that 
these mediate stimctures that encourage substitution mutations (Todorova and Danieli., 
1997).
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3.3,4.2 Base deletions/insertions
Deletion or insertion variants were seen in 9 individuals, with the deletion or insertion 
of one or more base pairs leading to a predicted shift in the reading frame occurring in 6 
cases. All deletion or insertion variants were located within or adjacent to repeated 
sequence; the slipped-mispairing model of mutagenesis explains this type of mutation 
(Chuzhanova et aL, 2003). One delins mutation was seen (3036-3037delinsC) where 
two nucleotides are replaced by a single nucleotide, causing a shift in the reading frame. 
This mutation is close to a run of C nucleotides that may be involved in the mutational 
mechanism.
In two cases an in-fr ame deletion was seen. In one individual with DMD the loss of a 
glutamic acid with 10307 10309delGAA was the only potential mutation observed, this 
has been reported once before and was associated with the milder DMD phenotype plus 
considerable retention of dystrophin by immunohistochemical staining (Becker et aL, 
2003). The case in this study had a similar phenotype; a more detailed description of the 
amino acid sequence context of this variant is given in Figure 3.2.4. This mutation 
occurs within an AGA repeat and is also within a palindrome, both types of sequence 
are implicated in generating mutations through slipped-mispairing of DNA during 
replication. The second in-frame deletion was the only potential mutation obseiwed in a 
patient with a diagnosis o f BMD, this was a novel deletion of a threonine 
(482_484delCCA T161del) within the actin binding domain of the dystrophin molecule 
(Figure 3.3.5). Several missense variants at bases within an adjacent a-helix have been 
associated with BMD. The crystal structure shows the deleted amino acid is located 
before a small a-helix, close to the site o f actin binding in the molecule. This report of 
an in-frame deletion is consistent with the BMD phenotype. Although only a single 
amino acid is lost in the protein the location of this small deletion suggests that it may 
disturb the structural arrangement o f the actin-binding site in that part of the protein. 
This deletion is within a CCA repeat with a symmetrical sequence directly adjacent, 
both are DNA sequences believed to influence slipped-mispairing during replication.
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Figure 3.3.5 Sequence alignment and protein structure of T161del. A.) The crystal 
structure o f  this region has been determined and a representation o f  the tertiary structure 
described in Norwood et al. (2000) has be re-drawn here. The actin binding site is 
shown in red and the yellow  indicates internal hydrophobic helices. M issense changes 
in the yellow  helices are believed to destabilise the tertiary structure o f  the region and 
suppress actin binding. This data shows that the T lb ld e l variant is located immediately 
before a small internal helix bend. B.) An alignment o f  a portion o f  the calponin 
homology domain o f  dystrophin (amino acids 135-180) against other human proteins 
known to share the same domain structure, Utrophin, A-Actinin and B-Actinin. Only 
amino acids that are different are shown. Dystrophin T161 and equivalent amino acids 
in related species are highlighted in red, and positions o f  reported missense mutations 
are in yellow: D165V, A168D, A171P, L172H (all associated with BMD). The actin 
binding site in this region is boxed and helical structure is indicated below the sequence.
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3.3.4.3 Variants with a potential effect on inRNA splicing
Variants affecting splicing have been described as pathogenic in a significant proportion 
of both DMD and BMD. There are several recognised types of splicing mutations, 
altering: Exonic Splicing Enhancer/Silencer (ESE/ESS) binding sites, the consensus 
splice site, branch sites within the intron and the introduction of cryptic splice sites. The 
consensus splice site was altered in one patient in this study. The G to T substitution at 
the consensus -1 position of exon 11 (1150-1G>T) is believed to cause dysfimctional 
splicing. In this case a reduction in spliceosome affinity for the 5' acceptor splice site of 
exon 11 is expected to influence the processing o f mRNA with an out of frame deletion 
of exon 11 consistent with the DMD phenotype in the patient. Changes in the consensus 
AG at the 3 ’ end of the intron are reeognised as a cause of the disorder. However, as the 
1150-1 G>T variant is novel to this study, the precise effect of this change has not been 
previously characterised at the mRNA level.
A further variant that could affect splicing is 1332-9A>G, this change has been 
reported before in one American patient and is believed to affect the 5' acceptor splice 
site of exon 12 (Mendell et aL, 2001). Dystrophin 1332-9A>G was the only potential 
pathogenic variant found in patient ID. 16. Using the Shapiro and Senepathy consensus 
scores this mutation does not significantly alter the spliee score at the exon 12 5' 
acceptor splice site, the variant increases the score from 85.16 to 85.31. However the 
variant is shown to generate a possible cryptic splice site at 1332-8 with a consensus 
score of 86.48, higher than the normal exon 12 5' acceptor splice site (Figure 3.3.4). If 
alternative splicing were to occur' this would introduce 8 nucleotides into exon 12, 
producing a shift in the reading frame resulting in a truncated transcript, consistent with 
a diagnosis of DMD in the patient.
One intronic change was not associated with a change in the consensus splice site of the 
adjacent exon, this was: 7098+105_7098+106insTATTTAATACTTTG (adjacent to 
exon 48), the only novel change in patient ID. 17. This novel variant can be detected by 
fluorescent PCR used in routine clinical testing and was not observed in a retrospective 
audit of over 500 chromosomes from the same population (data from the West of 
Scotland Regional Genetics Laboratory, Glasgow, UK). Analysis for consensus scores 
in the intron shows two potential 3' donor splice sites (score>70) the original exon 48 
splice site having a score of 84.67 and a second splice site having a higher score of
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87.59. The second predicted splice site at 7098+116 is 11 bp 3' from the insertion, 
presence of the inserted sequence does not change the consensus score of this potential 
splice site (Figure 3.3.6). ESE sites are binding sites for proteins involved in the splicing 
of RNA. Mutations altering ESE sites have been shown to alter splicing in DMD 
(Tuffery-Giraud et aL, 2004). Analysis for potential ESE sites shows that the insertion 
variant introduces an SC35 ESE site before the potential 3' donor splice site. ESE sites 
identified by this programme have been shown to cluster in regions where sites have 
been experimentally mapped (Figure 3.3.7).
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Figure 3.3.6 Analysis o f 7098+105_7098+106insTATTTAATACTTTG. A.) Results 
from the analysis o f  patient ID. 17 and a normal control using a fluorescent multiplex 
PCR o f  14 dystrophin exons (Yau et al., 1996). Observed fluorescence (Y axis) is 
shown against size o f  fragment (X axis). Under each peak is an exon label with an 
automatic calculation o f  size (bp) and peak area. Exon 48 in each sample is shown by 
the red arrow and is reported as 13.59bp larger in patient ID. 17 than the normal control 
exon 48 fragment. Sequencing showed a 14bp insertion in patient ID. 17 
(7098+105_7098+106insTATTTAATACTTTG). B.) Exon 48 amplicon sequence. The 
exon sequence is in upper case and the inserted sequence is highlighted in grey. A 
potential cryptic splice site is highlighted in red. The cryptic splice site has a consensus 
score o f  87.59 whilst the conventional donor splice site has a consensus score o f  84.67 
- the presence o f  the insertion does not alter these scores.
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Figure 3.3.7 Output from ESE finder for intron 48. A.) Output from ESE finder 
(http://exon.cshl.edu/ESE/) showing the predicted cryptic 3' donor splice site at 
7098+116 within intron 48, shown in red is the consensus splice site. Significant m otif 
scores for exon splicing enhancer SRp40 were present in the non-inserted intronic 
sequence. B.) output from ESE finder showing the predicted cryptic 3' donor splice site 
at 7098+116 within intron 48, shown in red is the consensus splice site. The inserted 
sequence is shown in grey. Significant m otif scores for exon splicing enhancer SRp40 
and an additional SC35 sequence were present in the intronic sequence with the 
insertion. C.) output from ESE finder showing the conventional Exon 48 3' donor splice 
site, the coding sequence is highlighted in green and the splice site in red. Two 
significant m otif scores for SRp40 were observed.
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3.3.5 Polymorphisms
Unidirectional sequencing showed several variants from the reference sequence in the 
normal control (Table 3.3.1), these have all been reported as common polymorphisms in 
the locus specific database for DMD (wvm.dmd.nl). Table 3.3.1 lists the polymorphism 
location and frequency in this study and in others. As some amplicons contain more 
than one common polymorphism and some polymorphisms were present in the control, 
these amplicons needed sequencing in the majority of cases. Only one variant (358- 
80T>C) found in Patient ID.2 has not been seen before, as this was observed with a 
recognised pathogenic mutation on the same allele in this patient it is most likely 
represents a rare polymorphism. Two of the polymorphisms although unique to this 
study were observed in several individuals (5448+169A>T; 8669-75C>G). All other 
variants found in the patient samples have been reported as polymorphic in other 
studies. The frequency of polymorphisms within the group of patients showed that some 
variants were observed at different frequencies to that reported in other european 
studies. One polymorphism 6290+27T>A in patient ID.l has only been reported twice 
before, in this instance the patient had a nonsense mutation on the same allele and was 
o f asian origin. A second rarely reported variant was seen twice in this study: 
8729 8734delinsTGGTCG: this is a compound of the reported polymorphisms 
8734A>G (Asn2912Asp) and 8729A>T (Glu2910Val), neither were seen independently 
in this study. When this change was first observed in this study only 8729A>T had been 
identified as a polymorphism and two previous reports of 8729_8734delinsTGGTCG 
classified the variant as associated with a severe form of BMD. In this study 
8729 8734delinsTGGTCG is seen once with a nonsense change on the same allele and 
once with potential splice site change on the same allele. Combining the occurrence in 
cis with a nonsense mutation with the relatively recent report of 8734A>G being a 
polymorphism this data suggests a non-pathogenic role for the 
8729 8734delinsTGGTCG variant.
8 6
3.3.6 Origin of mutations
For 12 of the 23 probands a maternal sample was available and carrier testing had been 
requested in all cases. Only 1 of the 12 cases was shown to be a new mutation, this 
lower than expected (30%) new mutation rate may be explained by the ascertaimnent 
bias for family history in some of the cases. Haplotype analysis performed in 6 o f the 
pedigrees showed that 1 of the mutations occurred on a grandpatemal haplotype and 5 
on a grandmaternal haplotype, once again selection o f cases with positive family history 
could have influenced these results.
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4.0 Discussion and future perspectives
4.1 Cognitive impairment and mutation in Dp71
In results 3.1 the reported possible phenotype genotype relationship between cognitive 
impairment and mutations in the Dp71 coding sequence was investigated. If mutations 
in this region were found more frequently in DMD/BMD patients with cognitive 
impairment than those without this would be an important finding. A phenotype 
genotype correlation is indicative of functional significance and would contribute to 
understanding dystrophin biology. The correlation could also have identified a mutation 
detection protocol for this sub-set o f patients. In total a cohort of 10 patients who had 
been diagnosed with DMD/BMD and cognitive impairment were studied. The 
percentage of the cohort in whom recognised mutations were found in the Dp71 region 
was 10%. In the subsequent study of 23 DMD/BMD patients where no cognitive 
impaiiment had been noted (results 3.3), 1 recognised mutation was found in 3 
unrelated patients in the Dp71 coding sequence (13%), this mutation has been 
previously reported in a patient with cognitive impairment (Moizard et aL, 2000) and in 
other patients where no neurological examinations have been reported (Leiden 
dystrophin mutation database http://www.dmd.nl). The comparison between the results 
presented here does not support the suggestion of a genotype-phenotype correlation 
within this region of the gene. We suggest that the distribution o f cognitive impairment 
amongst affected individuals is too broad to increase the sensitivity of a limited screen 
based on the presence of learning diffieulties. The reports o f point mutation in Dp71 
associated with mental retardation indicate that the individuals with mutation were all 
severely neuropsychologically impaired (Lenk et aL, 1993; Kekou et a l,  1999; Moizard 
et a l,  2000). It is possible that the neurological phenotype may only be associated with 
specific mutations or that the mutations which predispose to the additional phenotype 
may have a variable penetrance. Any genotype phenotype association in dystrophin is 
likely to be better defined with an increase in the number of reported mutations, in 
particular repeated reports of the same mutation.
To definitively answer the question of whether mutations in the Dp71 coding sequence 
are associated with DMD and cognitive impairment further investigation needs to be 
carried out on larger cohorts of rigorously diagnosed patients. As cognitive abilities in 
DMD can be affected by many factors, guidelines would need to be agreed for the
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accurate study of cognitive dysfunction to ensure a comparable cohort was being 
investigated.
4.2 The sensitivity and efficiency of dHPLC for analysing mutation in Dp71
In results 3.1 the sensitivity of dHPLC was equal to that of the sequencing, all variants 
within the coding region were detected by both methods. Although the polymorphism 
9974+13_9974+23(A)9~12 was not detected by dHPLC (Figure 3.1.7) the parameters 
used for dHPLC analysis detection were not specific to this region. The poly-A tract lies 
within the intron and is predicted to be fully melted at the temperatures used in this 
study. Avoiding a positive signal from the intronic polymorphism by dHPLC was 
efficient as it reduced the amount of post-dHPLC sequencing required.
4.3 Analysis of exon 70 in a cohort of 46 patients with DMD/BMD
In results 3.2 robotic amplification of exon 70 followed by dPIPLC identified four 
variants within a total of 46 patients who had been referred for DMD/BMD analysis and 
have no detectable deletion or duplication. This is a higher than expected level of 
detection for exon 70 if considered by proportion of coding sequence alone: 6.5% 
confirmed mutations in 1.2% of coding sequence screened. Based on this exon 70 could 
be considered as a candidate exon for a preliminary screen.
4.4 Investigations into the inheritance of a recurrent mutation in exon 70
In results 3.2 the R3391X (10171C>T) nonsense mutation was identified on a 
background of three different haplotypes and was shown to be a new mutation in at least 
one case. The mutation lies within a CGA codon, a sequence shown to have a 20 fold 
incidence of nonsense mutation compared to any other potential nonsense mutation site 
in DMD (Prior et aL, 1995). This data is therefore a report o f recurrent mutation within 
one of these sites and when the three cases here are included, makes this mutation one 
of the most frequently recorded point mutations in DMD. This data suggests that 
regional hotspots for mutation may exist in the dysti'ophin gene, however these may be 
difficult to identify as there are many potential sites for mutation within the dyshophin 
gene. Combinations of recurrent mutation within a single exon could identify exons
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with an increased likelihood of mutation. This should become more apparent as more 
mutation data becomes available.
The mitochondrial HVl studies in results 3.2 demonstrate that the local control 
population studied had a relatively low level of HVl diversity, further studies may 
establish a more accurate estimation o f this. There was also a high level of similarity in 
the dystrophin intragenic markers used and although only three individuals were 
analysed this suggests that the distribution of alleles in the Scottish population might be 
smaller than that reported in other populations.
4.5 dHPLC analysis of dystrophin exons 1-79 in 23 individuals
The large amount of data presented in results 3,3 represents a comprehensive study of 
the dystrophin gene sequence by dHPLC in 23 individuals. Robotic amplification by 
PCR and analysis by dHPLC and sequencing demonstrates a semi-automated approach 
that could be used to detect point mutation in any gene. This approach is relatively rapid 
and demonstrated a high level o f sensitivity for variance in the samples studied. 
Automation improved the accuracy and speed of the PCR and dHPLC process whilst 
reducing user time. Generating the dHPLC and sequence data in patient specific 
databases rapidly completed the analysis for each patient in turn. This approach may be 
suitable to the analysis of genes where the frequency of referrals makes waiting to 
complete a batch o f samples impractical. This is pertinent to DMD/BMD where the 
number of referrals may be small (in Scotland estimates are 3-18 per year) but requests 
for urgent testing are possible (e.g. the pregnant mother of a sporadic case could be 
offered prenatal mutation analysis based on the rapid detection o f the mutation in her 
son).
4.6 Sensitivity of the technique
Confirmation of the dHPLC results by sequencing in results 3.1 showed that the 
technique had a high level o f sensitivity for point mutations. Subsequent detection of 
novel variants and polymorphisms across the gene sequence in the group of 23 patients 
also demonstrated its ability to identify a range of variants (results 3.3). The proportion 
of mutations seen in the group of patients reported here is similar to those reported in 
other whole gene studies (Mendeil et aL, 2001;Bennet et aL, 2001). The overall
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sensitivity was 96% for either recognised or potentially pathogenic mutations. The 
sensitivity o f dHPLC is however dependent on sequence specific factors implying that 
some variants may not be detected by the technique. One example is the poly-A tract in 
dystrophin exon 68 where no variance by dHPLC was observed, this was shown to be 
most likely affected by the low local GC content, if  this situation is present in the 
coding sequence this may reduce the sensitivity of dHPLC at this point. This may be 
particularly relevant given the repeated occurrence of mutations after a run of the same 
nucleotide. All patients with tmncating mutations had a clear diagnosis of DMD. The 
one patient with DMD who had no detectable mutation could either represent a lack of 
sensitivity in the method, a mutation outside the region covered, or a duplication not 
detected by the fluorescent dosage multiplex PCR. The use of MLPA or mRNA studies 
could help determine the cause of mutation in this case. A combination of the multiplex 
PCR (Yau et aL, 1996) and dHPLC point mutation analysis should detect 90-94% of 
mutations in DMD (85-95% dHPLC sensitivity in DMD in 21 patients - depending on 
identity of variants). Introduction o f MLPA would detect a further 1% (missed 
duplications) and mRNA studies are expected to detect the remainder (Yan et al, 2004).
4.7 E fficiency o f  the technique
Although the Staden package facilitated the process, sequencing and data analysis is 
still costly and laborious. Compared to complete sequencing of the gene, dHPLC 
reduced the amount of sequence analysis by a factor of 10 and reduced costs by 
approximately 70-80%. The time taken to analyse the whole gene by automated 
sequencing or dHPLC was equal in the single example given here. The use of a 
heteroduplex based approach required the characterisation of the control allele sequence 
as well as that of the sample. Polymorphism accounted for a large proportion of the 
sequencing required with the control’s polymorphisms contributing significantly to the 
workload for each patient (Figure 3.3.2). Mixing the patient PCR products with PCR 
products containing each allele o f the common polymorphisms would distinguish the 
patient allele by dHPLC resolving both homoduplexes and heteroduplexes as well as 
screening for mutation at the same time. For example, screening for the polymorphisms 
occurring above a Ifequency of 0.2 in this study would require an additional 8 PCR 
products (which could be achieved using redundant wells on the 96 well plate). This 
would be expected to reduce the amount of sequencing required, further improving the 
efficiency of this dHPLC protocol. Advances in sequencing software are also expected,
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with an overall aim of fully automated analysis. Combining the automated sequencing 
of the whole gene as shown in figure 3.3.3 and a reduction in sequencing costs it may 
become possible that automatic sequencing of the entire coding region using these 
protocols will be equally (or more) efficient.
4.8 Distribution and types of mutation
The distribution of the mutations observed covered exons from across the gene. More 
than one recognised mutation was found in exons 70, 37 and 57. In exon 70 the 
mutation 10171C>T was found in three separate pedigrees. The three 10171C>T 
mutations were shown to have occurred independently by the use of intragenic markers 
and mitochondrial haplotypes (Results 3.2). Although this suggests that certain exons 
may have a raised likelihood of mutation, the distribution of reported mutations within 
the gene show that mutations are found in virtually all exons of the gene (www.dmd.nl). 
Thus sensitive analysis of the gene should consider the entire coding sequence.
The mechanism of each mutation was considered: showing that CpG dinucleotides and 
runs of nucleotides are common features of the mutations reported. Based on studies 
like this it may be possible to identify particular regions of the gene with an increased 
chance of a certain type of mutation. The selection o f samples with more than one 
affected family member introduced potential bias into studies on the origin of the 
mutations. With only one mutation shown to have occurred in the maternal germline, 
this is suggestive of a grandparental origin for many of the mutations however we could 
not determine the true grandparental ratio due to the aforementioned selection in certain 
pedigrees. Further haplotype studies to detennine if there is a sex bias to the origin of 
point mutations would help contribute to estimates of point mutation carriers in the 
general population.
4.9 Uncharacterised variants
The majority of variants detected were predicted to cause a truncated protein by their 
effect on the amino acid coding sequence and are all associated with a DMD phenotype. 
Only one of the intronic variants observed was a recognised cause of disorder whilst 
five changes identified in this study could not be confidently characterised as 
pathogenic by DNA results alone. These are the intronic variants 1332-9A>G,
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7098+105__7098+106insTATTTAATACTTTG, 10223+6T>C and the two in-frame 
deletions of 10099 10101 delGAA and 482_484delCCA. Only two of these changes 
(1332-9A>G and 1009910101 delGAA) have been reported before and were associated 
with disease in both cases. It has not yet been confirmed that small in-frame deletions 
are mutations of structural significance or rare deleterious polymorphism. The patient 
with the 10099 10101 delGAA variant had a diagnosis of a less severe DMD phenotype 
that is similar to the other reported case in the literature. Unfortunately no 
immunohistochemistry results were available as this may have revealed if, as in the 
previous report, dystrophin was produced and observed at the cell membrane. The 
similarity of phenotypes between the reported patient and the one in this study with this 
mutation is evidence to suggest that this variant does have a distinct effect on 
dystrophin function. The patient with the 482_484delCCA variant had a diagnosis of 
BMD, this could be expected from the suggested alteration in protein structure. No 
immunohistochemical results were available from this individual but the deletion was 
shown to be adjacent to an actin binding domain. As actin binding occurs in several 
domains of the protein, a local change in structure in a single domain may not be 
sufficient to fully remove binding but capable of lowering actin affinity to a level 
expected to cause a BMD phenotype. Investigation into the effects of the intionic 
variants (1332-9A>G, 7098+105_7098+106insTATTTAATACTTTG and 
10223+6T>C) on spliceosome recognition sites (Figures 3.3.6 and 3.3.7) was suggestive 
of an effect on splicing but remains inconclusive. Further work including mRNA studies 
would be an appropriate method for further characterisation of the intronic changes 
whilst the single codon deletions could both be candidate mutations for binding assays. 
The 10223+6T>C variant identified in results 3.1 may also be a candidate for mRNA 
analysis, unfortunately insufficient DNA was available for further analysis of the coding 
region in this sample. In all the cases with an unconfirmed variant, further family 
studies could exclude the change as a mutation if it is observed in unaffected males or 
suggest a pathogenic effect if  it is shown to have arisen in a recent transmission.
4.10 Analysis in BMD
Only one case of BMD was analysed for point mutation in this study (results 3.3). 
Determining the contribution of dystrophin point mutation in BMD is expected to reveal 
a more diverse range of mutation types (i.e. splicing, missense, deletion/insertions and 
nonsense/frameshifr mutations). There will be challenges in interpreting dystrophin
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missense changes and this may require investigations into their effect on the dystrophin 
structure. Furthermore, a significant proportion of BMD mutations have been found to 
have an unpredictable effect on RNA splicing. Some BMD mutations are shown to be 
nonsense mutations that do not lead to nonsense-mediated decay but (as has also been 
reported in other genes) affect splicing of in-lfame exons in the mRNA (Ginjaar et ah, 
2000; Fakusova et aL, 2001). This splicing removes the mutation-containing sequence 
producing a shortened mRNA. Also, the incidence of non-consensus intionic mutation 
(cryptic splice site/branch site mutation) has been reported at 44% of all point mutations 
in a cohort of 9 BMD patients (Yau et aL, 2003) and these have only been detected by 
PTT. Combined, these reports indicate that mRNA studies would be required to detect 
and characterise a larger proportion o f mutations in BMD than in DMD.
4.11 Polymorphism within the study population
A variety of polymorphisms were detected within the group of patients. The frequencies 
of several of the polymorphisms varied from that reported in other studies; this could be 
a result o f the geographical differences between populations. Some polymorphisms 
were novel to this study 358-80T>C, 5448+168A>T and 8669-75C>G with the latter 
two being observed in several individuals. These results suggest that this may be the 
first time these polymorphisms have been included in amplicons within a study o f the 
dystrophin gene. In two instances a rare polymorphism (each reported twice before in 
separate studies) was observed on the same allele as a nonsense mutation providing 
evidence for their non-pathogenic status. The first of these was 6290-27T>A seen in an 
individual of Asian origin. The second was the more complex change of 
8729 8734delinsTGGTCG which we believe is a compound of the 8729A>T and 
8734A>G polymorphisms, this had been previously associated with a severe form of 
BMD, but we believe this should be considered a polymorphism.
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